{ "entity_id": "B-003292", "folder": "National-Immunoglobulin-Governance-Advisory-Committee", "name": "National Immunoglobulin Governance Advisory Committee", "type": "Ministerial Council", "jurisdiction": "Commonwealth", "portfolio": "Health, Disability and Ageing", "website": "https://www.blood.gov.au/supply-system/governance-immunoglobulin-products/national-immunoglobulin-governance-committees", "data_status": "rich", "completeness": { "has_strategy_brief": true, "has_strategy_structured": true, "has_vision": false, "has_kpi_targets": true, "has_kpi_results": true, "has_strategy_overview": true, "has_legislation_text": true, "has_legislation_structured": false, "has_global_initiatives_text": false, "has_ideas": true, "has_artifacts": true, "n_ideas": 10, "n_legislation": 0, "n_artifacts": 4, "n_kpi_targets": 2, "n_kpi_results": 2, "n_outcomes": 1, "verified_own_data": true }, "strategy_profile": { "status": "published", "confidence": "high", "summary": "The National Immunoglobulin Governance Advisory Committee (NIGAC) is established by the National Blood Authority (NBA) General Manager (Chief Executive) under section 38 of the National Blood Authority Act 2003 (NBA Act) to assist with the performance of the NBA’s functions in relation to the National Immunoglobulin (Ig) Governance Program (the Program).", "official_site_url": "https://www.blood.gov.au/supply-system/governance-immunoglobulin-products/national-immunoglobulin-governance-committees", "source_documents": [ { "type": "annual_report", "title": "Annual Report", "url": "https://www.blood.gov.au/sites/default/files/documents/2025-10/NBA0920%20%E2%80%93%20NBA%20Annual%20Report%202024%E2%80%9325%20%28Working%20file%29%20-%20WCAG.pdf", "period": "2025", "confidence": "high" }, { "type": "corporate_plan", "title": "Corporate Plan", "url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "period": "2025", "confidence": "high" } ], "purpose": { "text": "The National Immunoglobulin Governance Advisory Committee (NIGAC) is established by the National Blood Authority (NBA) General Manager (Chief Executive) under section 38 of the National Blood Authority Act 2003 (NBA Act) to assist with the performance of the NBA’s functions in relation to the National Immunoglobulin (Ig) Governance Program (the Program).", "source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "source_page": 2, "source_deep_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf#page=2" }, "vision": null, "strategic_priorities": [ { "title": "Provide advice and make recommendations to the NBA to support the Program", "description": "Provide advice and make recommendations to the NBA to support the Program", "source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "source_page": 7, "source_deep_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf#page=7" }, { "title": "Provide advice and make recommendations to support cost effective and clinically appropriate governance, management and ", "description": "Provide advice and make recommendations to support cost effective and clinically appropriate governance, management and use of Ig products, including advice and recommendations in relation to each of the performance areas within the Program", "source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "source_page": 7, "source_deep_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf#page=7" }, { "title": "When requested by the NBA, provide advice or assistance to other parties on matters concerning the availability, governa", "description": "When requested by the NBA, provide advice or assistance to other parties on matters concerning the availability, governance, management or use of Ig products.", "source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "source_page": 7, "source_deep_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf#page=7" } ], "values": [ { "name": "Behave honestly and with integrity", "description": "", "source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "source_page": null }, { "name": "Treat everyone with respect and courtesy", "description": "", "source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "source_page": null }, { "name": "Act with care and diligence", "description": "", "source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "source_page": null }, { "name": "Comply with all applicable Australian laws", "description": "", "source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "source_page": null }, { "name": "Maintain appropriate confidentiality", "description": "", "source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "source_page": null }, { "name": "Disclose, and take reasonable steps to avoid, any conflict of interest", "description": "", "source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "source_page": null }, { "name": "Use Commonwealth resources in a proper manner", "description": "", "source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "source_page": null }, { "name": "Do not disclose or make improper use of inside information", "description": "", "source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "source_page": null } ], "outcomes": [ { "name": "Outcome 1: Governance and management of immunoglobulin products", "description": "The Program aims to ensure product use and management reflects appropriate clinical practice, represents efficient, effective and ethical expenditure of government funds, is in accordance with relevant national safety and quality standards for health care, and ensures that access to Ig products is consistent with the criteria for access determined by Governments.", "activities": [ "Development and maintenance of policies and procedures for access to Ig products", "Establishment and support of a national network of committees", "Evolving the criteria for access", "Development and implementation of a national ordering and outcomes database", "Improving performance", "Facilitating knowledge development", "Potential efficiency improvements" ], "source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "source_page": 8, "source_deep_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf#page=8" } ], "performance_measures": [ { "code": "Ig01", "measure": "Automated authorisation of access to Ig products", "target": "Feasible and appropriate", "latest_result": "N/A", "status": "Not achieved", "target_source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "target_source_page": 9, "result_source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-10/NBA0920%20%E2%80%93%20NBA%20Annual%20Report%202024%E2%80%9325%20%28Working%20file%29%20-%20WCAG.pdf", "result_source_page": null }, { "code": "Ig02", "measure": "Improved efficiency through streamlined product distribution", "target": "N/A", "latest_result": "N/A", "status": "Not achieved", "target_source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "target_source_page": 9, "result_source_url": "https://www.blood.gov.au/sites/default/files/documents/2025-10/NBA0920%20%E2%80%93%20NBA%20Annual%20Report%202024%E2%80%9325%20%28Working%20file%29%20-%20WCAG.pdf", "result_source_page": null } ], "document_alignment_terms": { "must_support": [ "The National Immunoglobulin Governance Advisory Committee (NIGAC) is established by the National Blood Authority (NBA) General Manager (Chief Executive) under section 38 of the Nat", "Provide advice and make recommendations to the NBA to support the Program", "Provide advice and make recommendations to support cost effective and clinically appropriate governance, management and use of Ig products, including advice and recommendations in relation to each of the performance areas within the Program", "When requested by the NBA, provide advice or assistance to other parties on matters concerning the availability, governance, management or use of Ig products." ], "watch_terms": [ "Automated authorisation of access to Ig products", "Improved efficiency through streamlined product distribution" ], "avoid_claiming_without_evidence": [] }, "review_note": "" }, "strategy_brief_md": "# National Immunoglobulin Governance Advisory Committee — Strategy Brief\n\n**Reporting period**: 2024-25\n**Corporate plan in force**: 2025-26\n**Corporate Plan**: [2025-26](https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)\n\n## Our purpose / purposes\n\n> The National Immunoglobulin Governance Advisory Committee (NIGAC) is established by the National Blood Authority (NBA) General Manager (Chief Executive) under section 38 of the National Blood Authority Act 2003 (NBA Act) to assist with the performance of the NBA’s functions in relation to the National Immunoglobulin (Ig) Governance Program (the Program). [[CP p.2](https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf#page=2)(https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf#page=2)]\n\n## How we deliver\n\n> The Program is delivered through a package of measures which implements an integrated national framework for governance and management of immunoglobulin products. [[CP p.7](https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf#page=7)(https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf#page=7)]\n\n## Government priorities for this department\n\n- Provide advice and make recommendations to the NBA to support the Program [[CP p.7](https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf#page=7)(https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf#page=7)]\n- Provide advice and make recommendations to support cost effective and clinically appropriate governance, management and use of Ig products, including advice and recommendations in relation to each of the performance areas within the Program [[CP p.7](https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf#page=7)(https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf#page=7)]\n- When requested by the NBA, provide advice or assistance to other parties on matters concerning the availability, governance, management or use of Ig products. [[CP p.7](https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf#page=7)(https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf#page=7)]\n\n## Outcomes\n\n### Outcome 1: Governance and management of immunoglobulin products\nThe Program aims to ensure product use and management reflects appropriate clinical practice, represents efficient, effective and ethical expenditure of government funds, is in accordance with relevant national safety and quality standards for health care, and ensures that access to Ig products is consistent with the criteria for access determined by Governments. [[CP p.8](https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf#page=8)(https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf#page=8)]\n\n**Key activities:**\n- Development and maintenance of policies and procedures for access to Ig products\n- Establishment and support of a national network of committees\n- Evolving the criteria for access\n- Development and implementation of a national ordering and outcomes database\n- Improving performance\n- Facilitating knowledge development\n- Potential efficiency improvements\n\n## Values and principles\n\n_Australian Public Service (APS) Code of Conduct_\n\n- Behave honestly and with integrity\n- Treat everyone with respect and courtesy\n- Act with care and diligence\n- Comply with all applicable Australian laws\n- Maintain appropriate confidentiality\n- Disclose, and take reasonable steps to avoid, any conflict of interest\n- Use Commonwealth resources in a proper manner\n- Do not disclose or make improper use of inside information\n\n## What they will measure themselves on this year (targets from 2025-26 corporate plan)\n\n| Code | Measure | Target | Source |\n|---|---|---|---|\n| Ig01 | Automated authorisation of access to Ig products | Feasible and appropriate | [CP p.9](https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf#page=9)(https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf#page=9) |\n| Ig02 | Improved efficiency through streamlined product distribution | N/A | [CP p.9](https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf#page=9)(https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf#page=9) |\n\n## How they performed last year (results from 2024-25 annual report)\n\n| Code | Measure | Result | Status | Source |\n|---|---|---|---|---|\n| Ig01 | Automated authorisation of access to Ig products | N/A | Not achieved | |\n| Ig02 | Improved efficiency through streamlined product distribution | N/A | Not achieved | |", "strategy_overview_evidence_md": null, "internal_strategy_evidence_md": "# National Immunoglobulin Governance Advisory Committee - Strategy, Performance, and Operating Profile\n\n**Generated at**: 2026-05-09T22:22:13.334624+00:00\n**Entity ID**: B-003292\n**Entity type**: Ministerial Council\n**Jurisdiction**: Commonwealth\n**Portfolio**: Health, Disability and Ageing\n**Website**: https://www.blood.gov.au/supply-system/governance-immunoglobulin-products/national-immunoglobulin-governance-committees\n\n> Draft generated from scraped source material. Treat this as an evidence pack for editorial review, not a final judgement.\n\n## Source Coverage\n\n| Source type | Count |\n|---|---:|\n| other-pdfs | 2 |\n| pages | 4 |\n\n## Executive Readout\n\n### Purpose\n\n- Medical Specialty Representatives*: NBA to appoint members based on\nEach SWG must have a minimum of 5 members consultation with Jurisdictional government\nand include: health departments and other relevant\n– Representation from both adult and stakeholders.\npaediatric specialities (where relevant) Each relevant SWG will include at least 1\n– Members from at least 4 jurisdictions representative from the relevant society:\n*Persons with clinical expertise and appropriate – Neurology Group - Australian and New\nqualifications to consider the clinical Zealand Association of\nappropriateness, safety and cost effectiveness of Neurologists(ANZAN)\nIg, including comparative outcomes of different – Haematology Group - Haematology Society\ntherapies. of Australia and New Zealand (HSANZ)\n– Immunology Group - Australasian Society\nof Clinical Immunology and Allergy (ASCIA)\n Source: `other-pdfs/SWG-20terms-20of-20reference.pdf (https://www.blood.gov.au/sites/default/files/documents/2024-08/SWG%20terms%20of%20reference.pdf)`\n- [Page 2]\nOFFICIAL\nRole\nPurpose\nThe National Immunoglobulin Governance Advisory Committee (NIGAC) is established by the\nNational Blood Authority (NBA) General Manager (Chief Executive) under section 38 of the\nNational Blood Authority Act 2003 (NBA Act) to assist with the performance of the NBA’s\nfunctions in relation to the National Immunoglobulin (Ig) Governance Program (the Program).\n Source: `other-pdfs/National-20Immunoglobulin-20Governance-20Advisory-20Committee-20-28NIGAC-29-20--.pdf (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- [Page 8]\nOFFICIAL\nThe specific implementation arrangements may vary according to the circumstances of different\njurisdictions or health services, within the objective of ensuring nationally consistent Ig governance\nand management outcomes.\n Source: `other-pdfs/National-20Immunoglobulin-20Governance-20Advisory-20Committee-20-28NIGAC-29-20--.pdf (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- Large jurisdiction 1\nrepresentative\nCommonwealth representative 1\nEpidemiologist 1 Persons with significant relevant experience, can\nevaluate the comparative outcomes of therapy\nand consider the clinical effectiveness, safety and\nHealth economist 1\ncost effectiveness of Ig compared to other\ntherapies.\n Source: `other-pdfs/National-20Immunoglobulin-20Governance-20Advisory-20Committee-20-28NIGAC-29-20--.pdf (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n\n### Role and Functions\n\n- [Page 2]\nOFFICIAL\nRole\nPurpose\nThe National Immunoglobulin Governance Advisory Committee (NIGAC) is established by the\nNational Blood Authority (NBA) General Manager (Chief Executive) under section 38 of the\nNational Blood Authority Act 2003 (NBA Act) to assist with the performance of the NBA’s\nfunctions in relation to the National Immunoglobulin (Ig) Governance Program (the Program).\n Source: `other-pdfs/National-20Immunoglobulin-20Governance-20Advisory-20Committee-20-28NIGAC-29-20--.pdf (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- Phone:\n1300 025 663\n(13 000 BLOOD)\nEmail:\nIgGovernance@blood.gov.au\nLast updated:\n07 May 2026\nBack to top\n Source: `pages/homepage.html (https://www.blood.gov.au/supply-system/governance-immunoglobulin-products/national-immunoglobulin-governance-committees)`\n- All\n2026\n2025\n2024\n2023\n2022\n2021\n2020\n2019\nNew BloodSafe eLearning Courses released\n07 Apr 2026\nCessation of supply of plasma-derived Factor IX\n07 Apr 2026\nNational Immunoglobulin Governance Program Update – November 2025\n19 Jan 2026\nNew James Isbister award sponsored by the National Blood Authority\n23 Oct 2025\n Source: `pages/news-latest.html (https://www.blood.gov.au/latest-updates)`\n- 640 0 obj\n<\n>/Filter/FlateDecode/ID[\n]/Index[628 21]/Info 627 0 R/Length 76/Prev 333197/Root 629 0 R/Size 649/Type/XRef/W[1 3 1]>>stream\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- endstream\nendobj\n629 0 obj\n<\n>/Metadata 41 0 R/Outlines 59 0 R/PageLayout/OneColumn/Pages 624 0 R/StructTreeRoot 104 0 R/Type/Catalog>>\nendobj\n630 0 obj\n<\n>/Font<\n>/XObject<\n>>>/Rotate 0/StructParents 0/Tabs/S/Type/Page>>\nendobj\n631 0 obj\n<\n>stream\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- hޤ�mO�0\u0010ǿ�_nB̏g;\u0012Bj\u0019eL�a\u0014�\u0006�E(\u0019�֦� \u0012|��m��t�\u0001S�^|�;�s?_��L0k\u0014�,�fZe��y\u0019�Ĥ��5�I�Šc� �66xow�~擺��=�?�O� ��1�A���v��p�I>�f~[��^^��iU�����o�5;�&o\n>ʣ��&�mn�����\u001a$�,��o>\u0015���aV+��HK�Z*>���5��Y������u\u0012:�1���\u0001.�� ����w[������\u0014\nQ->�Q���ӂ���\u001c���Q?l�E3\u001a?\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n\n### Strategic Priorities\n\n- Phone:\n1300 025 663\n(13 000 BLOOD)\nEmail:\nIgGovernance@blood.gov.au\nLast updated:\n07 May 2026\nBack to top\n Source: `pages/homepage.html (https://www.blood.gov.au/supply-system/governance-immunoglobulin-products/national-immunoglobulin-governance-committees)`\n- All\n2026\n2025\n2024\n2023\n2022\n2021\n2020\n2019\nNew BloodSafe eLearning Courses released\n07 Apr 2026\nCessation of supply of plasma-derived Factor IX\n07 Apr 2026\nNational Immunoglobulin Governance Program Update – November 2025\n19 Jan 2026\nNew James Isbister award sponsored by the National Blood Authority\n23 Oct 2025\n Source: `pages/news-latest.html (https://www.blood.gov.au/latest-updates)`\n- 640 0 obj\n<\n>/Filter/FlateDecode/ID[\n]/Index[628 21]/Info 627 0 R/Length 76/Prev 333197/Root 629 0 R/Size 649/Type/XRef/W[1 3 1]>>stream\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- endstream\nendobj\n629 0 obj\n<\n>/Metadata 41 0 R/Outlines 59 0 R/PageLayout/OneColumn/Pages 624 0 R/StructTreeRoot 104 0 R/Type/Catalog>>\nendobj\n630 0 obj\n<\n>/Font<\n>/XObject<\n>>>/Rotate 0/StructParents 0/Tabs/S/Type/Page>>\nendobj\n631 0 obj\n<\n>stream\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- hޤ�mO�0\u0010ǿ�_nB̏g;\u0012Bj\u0019eL�a\u0014�\u0006�E(\u0019�֦� \u0012|��m��t�\u0001S�^|�;�s?_��L0k\u0014�,�fZe��y\u0019�Ĥ��5�I�Šc� �66xow�~擺��=�?�O� ��1�A���v��p�I>�f~[��^^��iU�����o�5;�&o\n>ʣ��&�mn�����\u001a$�,��o>\u0015���aV+��HK�Z*>���5��Y������u\u0012:�1���\u0001.�� ����w[������\u0014\nQ->�Q���ӂ���\u001c���Q?l�E3\u001a?\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- 5�NSNF\b���tԫ�'\u0005\u0013|�\u0014�őt�`\u001ar��7�lο�G1�Ń��\b&˛nW��UY]�Ӳ�Uu��\u000f�y�l���ñ\u001f��R��|�[\u0013IH��� �\u001c�\n1���IU\"Z\u0011�g�_$�ݮ�q}�T�$�=��\u001b �����x\u0013P\"@FZǹ!���\".4JD.\u0001�M\u001a2��x�lN\u0001PR\u0004_�d�\u0016�Nƹ\u0002�1wH�%[R.J��ɘ�$ӚZM�L��\n�\u001f��%Y�?I&�H�r�$ɨfXcR�-\u0004��C��.Ǿ�񗣃�;��h�ޟM����{\u0006e��j������o��,��j��\u0019��r!U��耩��Wt޺�\u0005�V\u0002#�\u001d\u00069 ��.}���\b-�+�\u001c�tX�\"$g\u0011��&afCו i��\u0017�p\u0019���f�d\u0013�R�+��U�Q!��Y�X!�\u0018K[�$|\b>^\u0001HÜ���r���S�\u0016N�_\u0006���yvvxxr�\u0018yk�5���D\u0017�Ζo$Ҿ����\u0010�PAmZ��X�\f�D\u0011�\n+\fHC\u0001Z�H�\u0003���ؚ�Il���.�\u0010\u0016��<碴�����Z\u001f,}���\u0013�(dS�Mҡ��6��H2�S�\u0011Zx�գ�\u0006}��&_�\u0013�p����`��p�\f��!��\u0006�\\\u001am;�\u0002��\u0016`�NN\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- H�\\��j�@\u0010��}��l/��q�\u0001 ���\\�@�>��M*4�l�E޾���\u0016*�|��3�蘮����'����ݹ�\u001cz�\u0005w\u001e.�ufO��t};�\\���ԌI\u001a7��ɝ��0$umҷ�x���ܬ�a�n��%t.��hn>ֻ[��.���N�O&3˥��!&zj����L:o��vq���wq�_��ut���sʴC��cӺ���K�,\u001eKS?�c�8��[\u0017����lBR\u0017\bβ�\u0017���\u0010���\u0012�˜��\u000br\u0001.�%X�\u0002��\u0015X�\n�d\u000b�'߃\u0017�\u0005xE^E\u0016�\u0015�\u0015�\u0015�\u0015�\u0015�\u0015�\u0017�\u0017�\u0017�\u0017�\u0014�5y\nf��\u001e�\u001c\u001fT]1��\u0015{�Ћ�A᠌Q�(\u001d\u0014\u000e�x��ٻ�w���M�pS���]��Tz*\n>stream\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- H��V�N�H\u0010}�W�c���}����H \u00016+\u00023���*��L0lV\nf�\u0011��OU�\u0012�� 싻;�˩S]ǙdA<ޖ�媄\u000f\u001f�qY.W��װ���\u001e�œI�\u0013\u0016�0�\u0013\u0007��L\u0018c@k�h��� s2Eë����}\u000e���:�B��ӧ���nY��;��q2=� �2\u000e\u0002��@\b�5D\u001c�췊3��:�\u0012�6�\b���xNN\u0003 'EY\u0016�=��0Ӆi8S/Q�\u0014E�;�\u001c��2�\u0014d�] �o#\f�%\u0016�g�by\u0007S��ϏfSd�~�#��`�d\u001a�bZ9\u0010X0.�<�\u001b�I\u0016\b z��A�\u0019�\u0012�\u0015ԛ'\u0010�&_B\u0015\by�D�btq\u0012F\nF�sv\u0014\n|���,���E4|~_�N2%\u001cӺ���7{W��D�6\u000fP,��M�\b\u0015��4��q,,���m��\u0019n��\b>Y�>n�Z٭��Ԁ�I4\u001a��\\�Ad�`��&� >��p�\u0010�\u0016Ϊ�è\n��!��\u001c�Ƥ��j\u0013ij\n�i�i<�τ>���P\u001d�\u0010\u0003\na��>M\u001d�z\u001a�\u000b�;�d\u0015J�qd+3F1��3�\u0018�#\u0005�I��t�2i,�?\u0006,҃\u0016�����1À\u00043v!\u000e&\u0016�:l�\u000f���\u001b@�$h��z�\u0004(�\\�d��\u0004�\u001cN�`\"�F�|\u001c�&�2\\\f�U�\\��qs\u0006~�(�H�i��\u0013t/I\u0015�\u000b��Qg~8�a��'��\u0017�<\u000f#�u\u0011F\u0018�4�\u001c&�\u000e�0��\b\u001d�*��v���F-�pi*��x\u0010�!��|\n�y\u001cb\f\f~�u�*8C@�\"����6��Q���\u0019w�����,F�)\u0002%��\u0018���Jx\u0015F��\u000bZ�|�\u000f%ä��EI�\u0017����(b�{f��\u0018�4-������sN:�P���\\�v�\"��,�;T��;݊pԪ0��kX�[eI?$}���fD��Q\u001ez��5[��>^f��m7]�H,��ڦ��F�?B�i����\u0006����,��T \u0001�,\u0011~�S���� bs��\u000e`\u0005����\u0007\\���n�=b[�jK��&gL��\u001cx1�\u0015.�V��bCL�}i�5�\u0019�]\"\n�.\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- H�\\��n�@\u0010E���^&�ȯ� YH\u0004\u0012��<4�|��\u001bb)ؖ1\u000b�~��F\u0019i��c��{�JM����}7���44�0�S׷S�\u000e�� �\u0018�]��k�f��Z>�K=&i\\|�_�p���!�*���\u000f��tw\u000f�v8��$�1�a���{��=<��p\u001bǏp ��2�^�6��o����\u0004�.˞�m|�������/~�����:�L3��:�M���\u001c�*������k�����\u001a�\u001dO�{=%U�\u001fgY���L~\u0006��+�\u0005��;�+�\u0015�F��Uə%f�99\u0007\u0017�\u0002\\�K��\u0005��\u001e�d\u0005\u001b���,�Yҳ�g�!o\"\u000bs\u0005��\\A�0W�+�\u0015�\ns\u0005��\\A�0W�+�\u0015�\ns\u0005��\\Yrٕ�+aW���] �\u0012v%�ʳ+��<�=�=�=�=�=�=�=�=�=�===<�s\u0014s�s\u0014s�s\u0014s�s\u0014s�s\u0014s�{W�]9S��ܻb�ʽ+��ܻb��B~\u0001�\u0007E\u000f�\u001e\u0014=({P���Aу�\u0007C\u000fF�����o�7�\u001b�\n�F�����o�7�\u001b�\n�F��\nYE���� /��\\.����8�S��js��xL����|�dv}���\u0018���Ux'\u0005\u0018g/\n4\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- H�\\�Qk�@\u0014���\u0015��>\u0014\u0013u�MA\u0002ۤ�<�]6�\u001f`t�\u00156�L�C�}��.����3���5�춻�O.���v\u001f&w�c��e��6�C8�1[\u0016�����j�o�͘�y�LἋ�!�k�����)��ݏn8��,O]H}<��ߛ�����q�\u001b�!Nn��kׅ�\u0005�6�[s\u000e.��=�:��O�\u0007��o��m\f�����i�.\\Ʀ\n�����\u000b;֮~�c����w�Zq����iRV\u0017X�X��xE^�\u001fɏ�%הXS\u0016�\u0002,d1��3�ɘk*��Jr ��\u0015ؓ=�9՜�d\u0005ӡ�C�!o�[�\u0016�L~\u0006���x���������������������������� �(�(�\u0014d\n3\u0005��LA�0S�)�\u0014d\n;\n:\n߹��\u000b�%��O`v\u0017t\u0017v\u0017t\u0017v\u0017t\u0017v\u0017tWvWtWz*<��\nO���S��Tz*<��\nO���S�i'\f��$a��p�s�^S�\u0011�?�yv1�}\f�_�8��v�}\n0u�݇\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n\n## KPIs, Targets, and Where They Are At\n\n- Phone:\n1300 025 663\n(13 000 BLOOD)\nEmail:\nIgGovernance@blood.gov.au\nLast updated:\n07 May 2026\nBack to top\n Source: `pages/homepage.html (https://www.blood.gov.au/supply-system/governance-immunoglobulin-products/national-immunoglobulin-governance-committees)`\n- All\n2026\n2025\n2024\n2023\n2022\n2021\n2020\n2019\nNew BloodSafe eLearning Courses released\n07 Apr 2026\nCessation of supply of plasma-derived Factor IX\n07 Apr 2026\nNational Immunoglobulin Governance Program Update – November 2025\n19 Jan 2026\nNew James Isbister award sponsored by the National Blood Authority\n23 Oct 2025\n Source: `pages/news-latest.html (https://www.blood.gov.au/latest-updates)`\n- 640 0 obj\n<\n>/Filter/FlateDecode/ID[\n]/Index[628 21]/Info 627 0 R/Length 76/Prev 333197/Root 629 0 R/Size 649/Type/XRef/W[1 3 1]>>stream\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- endstream\nendobj\n629 0 obj\n<\n>/Metadata 41 0 R/Outlines 59 0 R/PageLayout/OneColumn/Pages 624 0 R/StructTreeRoot 104 0 R/Type/Catalog>>\nendobj\n630 0 obj\n<\n>/Font<\n>/XObject<\n>>>/Rotate 0/StructParents 0/Tabs/S/Type/Page>>\nendobj\n631 0 obj\n<\n>stream\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- hޤ�mO�0\u0010ǿ�_nB̏g;\u0012Bj\u0019eL�a\u0014�\u0006�E(\u0019�֦� \u0012|��m��t�\u0001S�^|�;�s?_��L0k\u0014�,�fZe��y\u0019�Ĥ��5�I�Šc� �66xow�~擺��=�?�O� ��1�A���v��p�I>�f~[��^^��iU�����o�5;�&o\n>ʣ��&�mn�����\u001a$�,��o>\u0015���aV+��HK�Z*>���5��Y������u\u0012:�1���\u0001.�� ����w[������\u0014\nQ->�Q���ӂ���\u001c���Q?l�E3\u001a?\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- 5�NSNF\b���tԫ�'\u0005\u0013|�\u0014�őt�`\u001ar��7�lο�G1�Ń��\b&˛nW��UY]�Ӳ�Uu��\u000f�y�l���ñ\u001f��R��|�[\u0013IH��� �\u001c�\n1���IU\"Z\u0011�g�_$�ݮ�q}�T�$�=��\u001b �����x\u0013P\"@FZǹ!���\".4JD.\u0001�M\u001a2��x�lN\u0001PR\u0004_�d�\u0016�Nƹ\u0002�1wH�%[R.J��ɘ�$ӚZM�L��\n�\u001f��%Y�?I&�H�r�$ɨfXcR�-\u0004��C��.Ǿ�񗣃�;��h�ޟM����{\u0006e��j������o��,��j��\u0019��r!U��耩��Wt޺�\u0005�V\u0002#�\u001d\u00069 ��.}���\b-�+�\u001c�tX�\"$g\u0011��&afCו i��\u0017�p\u0019���f�d\u0013�R�+��U�Q!��Y�X!�\u0018K[�$|\b>^\u0001HÜ���r���S�\u0016N�_\u0006���yvvxxr�\u0018yk�5���D\u0017�Ζo$Ҿ����\u0010�PAmZ��X�\f�D\u0011�\n+\fHC\u0001Z�H�\u0003���ؚ�Il���.�\u0010\u0016��<碴�����Z\u001f,}���\u0013�(dS�Mҡ��6��H2�S�\u0011Zx�գ�\u0006}��&_�\u0013�p����`��p�\f��!��\u0006�\\\u001am;�\u0002��\u0016`�NN\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- H�\\��j�@\u0010��}��l/��q�\u0001 ���\\�@�>��M*4�l�E޾���\u0016*�|��3�蘮����'����ݹ�\u001cz�\u0005w\u001e.�ufO��t};�\\���ԌI\u001a7��ɝ��0$umҷ�x���ܬ�a�n��%t.��hn>ֻ[��.���N�O&3˥��!&zj����L:o��vq���wq�_��ut���sʴC��cӺ���K�,\u001eKS?�c�8��[\u0017����lBR\u0017\bβ�\u0017���\u0010���\u0012�˜��\u000br\u0001.�%X�\u0002��\u0015X�\n�d\u000b�'߃\u0017�\u0005xE^E\u0016�\u0015�\u0015�\u0015�\u0015�\u0015�\u0015�\u0017�\u0017�\u0017�\u0017�\u0014�5y\nf��\u001e�\u001c\u001fT]1��\u0015{�Ћ�A᠌Q�(\u001d\u0014\u000e�x��ٻ�w���M�pS���]��Tz*\n>stream\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- H��V�N�H\u0010}�W�c���}����H \u00016+\u00023���*��L0lV\nf�\u0011��OU�\u0012�� 싻;�˩S]ǙdA<ޖ�媄\u000f\u001f�qY.W��װ���\u001e�œI�\u0013\u0016�0�\u0013\u0007��L\u0018c@k�h��� s2Eë����}\u000e���:�B��ӧ���nY��;��q2=� �2\u000e\u0002��@\b�5D\u001c�췊3��:�\u0012�6�\b���xNN\u0003 'EY\u0016�=��0Ӆi8S/Q�\u0014E�;�\u001c��2�\u0014d�] �o#\f�%\u0016�g�by\u0007S��ϏfSd�~�#��`�d\u001a�bZ9\u0010X0.�<�\u001b�I\u0016\b z��A�\u0019�\u0012�\u0015ԛ'\u0010�&_B\u0015\by�D�btq\u0012F\nF�sv\u0014\n|���,���E4|~_�N2%\u001cӺ���7{W��D�6\u000fP,��M�\b\u0015��4��q,,���m��\u0019n��\b>Y�>n�Z٭��Ԁ�I4\u001a��\\�Ad�`��&� >��p�\u0010�\u0016Ϊ�è\n��!��\u001c�Ƥ��j\u0013ij\n�i�i<�τ>���P\u001d�\u0010\u0003\na��>M\u001d�z\u001a�\u000b�;�d\u0015J�qd+3F1��3�\u0018�#\u0005�I��t�2i,�?\u0006,҃\u0016�����1À\u00043v!\u000e&\u0016�:l�\u000f���\u001b@�$h��z�\u0004(�\\�d��\u0004�\u001cN�`\"�F�|\u001c�&�2\\\f�U�\\��qs\u0006~�(�H�i��\u0013t/I\u0015�\u000b��Qg~8�a��'��\u0017�<\u000f#�u\u0011F\u0018�4�\u001c&�\u000e�0��\b\u001d�*��v���F-�pi*��x\u0010�!��|\n�y\u001cb\f\f~�u�*8C@�\"����6��Q���\u0019w�����,F�)\u0002%��\u0018���Jx\u0015F��\u000bZ�|�\u000f%ä��EI�\u0017����(b�{f��\u0018�4-������sN:�P���\\�v�\"��,�;T��;݊pԪ0��kX�[eI?$}���fD��Q\u001ez��5[��>^f��m7]�H,��ڦ��F�?B�i����\u0006����,��T \u0001�,\u0011~�S���� bs��\u000e`\u0005����\u0007\\���n�=b[�jK��&gL��\u001cx1�\u0015.�V��bCL�}i�5�\u0019�]\"\n�.\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- H�\\��n�@\u0010E���^&�ȯ� YH\u0004\u0012��<4�|��\u001bb)ؖ1\u000b�~��F\u0019i��c��{�JM����}7���44�0�S׷S�\u000e�� �\u0018�]��k�f��Z>�K=&i\\|�_�p���!�*���\u000f��tw\u000f�v8��$�1�a���{��=<��p\u001bǏp ��2�^�6��o����\u0004�.˞�m|�������/~�����:�L3��:�M���\u001c�*������k�����\u001a�\u001dO�{=%U�\u001fgY���L~\u0006��+�\u0005��;�+�\u0015�F��Uə%f�99\u0007\u0017�\u0002\\�K��\u0005��\u001e�d\u0005\u001b���,�Yҳ�g�!o\"\u000bs\u0005��\\A�0W�+�\u0015�\ns\u0005��\\A�0W�+�\u0015�\ns\u0005��\\Yrٕ�+aW���] �\u0012v%�ʳ+��<�=�=�=�=�=�=�=�=�=�===<�s\u0014s�s\u0014s�s\u0014s�s\u0014s�s\u0014s�{W�]9S��ܻb�ʽ+��ܻb��B~\u0001�\u0007E\u000f�\u001e\u0014=({P���Aу�\u0007C\u000fF�����o�7�\u001b�\n�F�����o�7�\u001b�\n�F��\nYE���� /��\\.����8�S��js��xL����|�dv}���\u0018���Ux'\u0005\u0018g/\n4\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- H�\\�Qk�@\u0014���\u0015��>\u0014\u0013u�MA\u0002ۤ�<�]6�\u001f`t�\u00156�L�C�}��.����3���5�춻�O.���v\u001f&w�c��e��6�C8�1[\u0016�����j�o�͘�y�LἋ�!�k�����)��ݏn8��,O]H}<��ߛ�����q�\u001b�!Nn��kׅ�\u0005�6�[s\u000e.��=�:��O�\u0007��o��m\f�����i�.\\Ʀ\n�����\u000b;֮~�c����w�Zq����iRV\u0017X�X��xE^�\u001fɏ�%הXS\u0016�\u0002,d1��3�ɘk*��Jr ��\u0015ؓ=�9՜�d\u0005ӡ�C�!o�[�\u0016�L~\u0006���x���������������������������� �(�(�\u0014d\n3\u0005��LA�0S�)�\u0014d\n;\n:\n߹��\u000b�%��O`v\u0017t\u0017v\u0017t\u0017v\u0017t\u0017v\u0017tWvWtWz*<��\nO���S��Tz*<��\nO���S�i'\f��$a��p�s�^S�\u0011�?�yv1�}\f�_�8��v�}\n0u�݇\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- ��JR%���B���j5��\u001c+��)\u0014�g(�ً%\u0006�!P�\u0013�\u000b\u0003�TPi˼����JWe�`�X�1�FK���W\u001f\u001e�ć�3�=\u0016k�6\u0006�n����9\u0016\u0002M\u0003�3\u0017f����\u001f�tJ�^�*�\u001c�_2�\u0007|r��\n=�z\u001b��(m\u000f�f��Hb�,K�O���>�eA�c>�\u0010���i\u0017\u0001�Fꡦ�\u0012h�E\n����y�{�\b�vC}ּ�ԉ\u0015��D�j했�D����R���V�����=\\\u000eզ\"D�\u0005��j0p�ą�x����_��\u001d\u0017+UI�U�\u0010��z�W�\u0016l�� 8A�]���_a}��k\u0015����T^��H\u0004\u0006��\u0015:H(\u001c��\bbr�a��B��{\"�pL�9r�]���\bf����9�\u001dG�_/<���nf8��fؐ�8a5r�\u0006촞����N���\u0005�~�T\u001f�w�!�d�4�$i I�4�H�B�Q�dlI?�D[m\u001b\u0006^ϑbn �?Ǥr\u0004�bZ1S� S�)Z�ZZ了L(�%�s\u000e�~�D\n����\u0012\u0013)�R�N)B6J��CY6\u0016\u001e5�a�M���z��>���I��\u001dha\u0011� <�s\u0003ء�e�!,)cs�Q��l�\u001aW*��Zz��^\u001b�uư�\f\u001d\u001c��~\u001b��v��w��P�:t��é�U�:�+o�\u0013��ڦ�\u0019K���XywG<��G��;�ĥ��\u0017{WM�\u001a�W��\n��o\nrK��p4��>��;�o\\�hl-M�.��쵵�M���`�ɋ���=�����\u0016d\u0001Eq}g.�\u001e?�_��\u0005���\u000e����snH\u001d\"\"�\u0014\f$<\u0012�\u0016�\u0010(\u0002F �\u0010\b�\u0010\b�$\u0004�<+�#C\u000b\n�C\u001eq� �@c\u0012����e}��Tq(-b�c\u000b�:�\"-\u00130Tk�\n����=�^B\u0012��xg~����={\u001e�?�}'7j�\nDG@���c�r��\u0017N�ݺ]ܪ6\"��V|�yw�\u001e֩�ʺ[�*[՚l�_�'U�;\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- H�d�w\\TW\u0016��;#Q\f (V|30���`�X\"b7&\u000b\u0016� �\u0006J�Œ�.v�-�\u001b��$����6�=q�Y���d��d�(�\f\u0002\"\u0016T,Q��3\u001a\u0013��}����������4�B\b�\u001a�\u0010\u00161̶-@�\\�995+%�#oQ9@�@#���kXV7=\nx���'3��d�^���Z�ʟ�9/#���r�u>��ojzJ����π�3z@����q�W\u0003�?�~�ԬܹqK>�\u0004ti�ǷΜ��Rz�\"\u0010��\u0001\u001azg����X��?b�\u001eo�L�J?Q��H�3�~�eϚ���\u0014\u0011��6������%N_��\u0002�\u000bJ��0��\u0014�.�\u0011[��|\u0011\u0019\\��FP�J�/���\u0017ix�a���5ȯ;\u0001x�q�\u0001���'�6�s��=��u\u0011�j�X�\u001e�i\u000f\n$\fQ��\u0016�\"ZJ+i\u0003m�ʹ�\n�\u001d��TA7�ɭ8�{p\"��$\u001eǩ�ϫx\u0003�㫢�S�H+ �v�]�e�,���Z��V�!�r^�T�*Z�)����fZkn����5����ǿ( 5`I�'\u0001O\f/��\u0011`X�`��\u0011nD\u001a�Fo���m�3\u0016\u0018+��\u0016����o1,VK���%Ғh�h�l�ne���embmjmimkmo\n�v�\u000e��X�\u00039�;�\u00124�\u0006\u001b�\n!�!\u0019!\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- �|̟��\u0003h\u0003�ѵ${��Z�ʣ�]I\u0006���^.2YO�\u0003*u\u0014�W#a�c��\u0001\u001b�:��V���I��xkՅ�\u0018�\\\u0001�\u0006�ԍ8��K��\nи��^S�̥MM4�LS�\u001aI%�\\�\u001b@F��)MSm)>H�h�\u0018�JRK+��7�1���4[�B�:���4ao\u001d1I.�oF�u\u000bv��7�\u0011�]��.\n<<2I���)'�%����7��^�\u0016�sie�\u0012M\u0015��W\u001a�xyY�7�\u0001\u001a��:��#$�y��I�\u0014aJNI$�7�oG����\u001c�<%Ԑi�J\u0015��%��02�QMer6\u0018�:L�\u0011�����ejK8$�>���XZ����\u001b�i�HӋod��P�\u000b�)E�>L�T��Ot�:Q��[%�\u0001�\u0004i]B��6ғ�&�ь�$��>�x\u0003\u0019KI�\u0003E��.�\u000f(�h�F\u0016��\u0014��F�\u0004j�P�kS�^�I#΄*4����`H#Q���z^p��I��\b�oJ�^_�\u0003x\n\u0017\u0017P����#le��Z�.#�I5���F��*��M9.h�hT!\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- 9$���x\u0003Ezз���\u0012��暔�R-5���\u0010�\u001a�Mn�#q�4�4��#h\u00027�PU\u0015,�Mg\u0004�G���X�����\u001b�c)i5[�B�:���4ao\u001d1I.�\u0006�\u0011�]BݭO\u0019zQ$�:\u0010�ӒO\u000f+���F�\u0017\n�y���&�t#I�+\u0019y~,��qu\u000bH��7�+Q��t�&��\u001bc-F@#F�\u0015f馜�4I4*\u0010���Y|�\u001b�h�Z\u0016�r��\\��*F�S[��T�\u001a�i���\u001cƚ��[$\u0006�\u0011�����ejk8$�<�5jǥ�g�\n�\nu*(,�F�\u0019GP\u001am�!u\u0005*o)�$\u001ai҅\b��a.���R�)�\u0012�N\\�y$�:1�%&�k��\u0003x\u000f�е ?�ѵ${��Z�ʣ�]I\u0006���^.2YO�\u0003*u\u0014�W#a�c��\u0001\u001b�:��V���I��xkՅ�\u0018�\\\u0001�\u0006�ԍ8��K��\nи��^S�̥MM4�LS�\u001aI%�\\�\u001b@F��)MSm)>H�h�\u0018�JRK+��7�1���4[�B�:���4ao\u001d1I.�oF�u\u000bv��7�\u0011�]��.\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n\n## Key Metrics\n\n| Values found | Evidence | Source |\n|---|---|---|\n| $2 | hޤVm��8\u0010�+���\n�\u001e�K�J�Rn9]i\u0017hi\u000f�!\u000b>6R (��߱�K�\u0002m9�����x���~\"\u0014�Dh\"� �\u0010M\u0015\u0011�X����1Èd� �9��q� S\nGA�jK�$�,\u0010�\bp\f!5\u0001�熀�����}\\�n�*�N���}p�\u0010��s���t\u001e}XͲy�ZD�d�^\u0015�~�M�\\|x�s�!�w\\1˓u��>GJ\u0006�_�փI\u001a\n_����E��Ս�?ٗU��\u001c&\u0014܃5$2N��K1\u0001����Oaɤ�\u0007؝�k\\|��\u0007\u001fi����\u0001gRq_t+��\u0014V�/v��0J� g�\u001a]�ATy��0^��ʗ\u0012�-��\u0012.t\u0015Es��$\u0002��\u0011�E*����a?��̭J�(��C�3t% �\u0006�C�~t��D&��7�;�h�M�EAD���}�߄\u0006;�\f\u0001�PӰԍ�I�y7�,����2%�\u0003�i��\u001b���E_G����m��q\u0014\u0016�e���K���e�\u0006ӸJG`:�\u0012y7k�\u0016�#H��-�\u0012-\u000f�8�+��E!)m\"f��\u0011�]È�*�V\u001d@���a\nqb�}�\u0006 | `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)` |\n\n## Key Achievements\n\n- Phone:\n1300 025 663\n(13 000 BLOOD)\nEmail:\nIgGovernance@blood.gov.au\nLast updated:\n07 May 2026\nBack to top\n Source: `pages/homepage.html (https://www.blood.gov.au/supply-system/governance-immunoglobulin-products/national-immunoglobulin-governance-committees)`\n- All\n2026\n2025\n2024\n2023\n2022\n2021\n2020\n2019\nNew BloodSafe eLearning Courses released\n07 Apr 2026\nCessation of supply of plasma-derived Factor IX\n07 Apr 2026\nNational Immunoglobulin Governance Program Update – November 2025\n19 Jan 2026\nNew James Isbister award sponsored by the National Blood Authority\n23 Oct 2025\n Source: `pages/news-latest.html (https://www.blood.gov.au/latest-updates)`\n- 640 0 obj\n<\n>/Filter/FlateDecode/ID[\n]/Index[628 21]/Info 627 0 R/Length 76/Prev 333197/Root 629 0 R/Size 649/Type/XRef/W[1 3 1]>>stream\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- endstream\nendobj\n629 0 obj\n<\n>/Metadata 41 0 R/Outlines 59 0 R/PageLayout/OneColumn/Pages 624 0 R/StructTreeRoot 104 0 R/Type/Catalog>>\nendobj\n630 0 obj\n<\n>/Font<\n>/XObject<\n>>>/Rotate 0/StructParents 0/Tabs/S/Type/Page>>\nendobj\n631 0 obj\n<\n>stream\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- hޤ�mO�0\u0010ǿ�_nB̏g;\u0012Bj\u0019eL�a\u0014�\u0006�E(\u0019�֦� \u0012|��m��t�\u0001S�^|�;�s?_��L0k\u0014�,�fZe��y\u0019�Ĥ��5�I�Šc� �66xow�~擺��=�?�O� ��1�A���v��p�I>�f~[��^^��iU�����o�5;�&o\n>ʣ��&�mn�����\u001a$�,��o>\u0015���aV+��HK�Z*>���5��Y������u\u0012:�1���\u0001.�� ����w[������\u0014\nQ->�Q���ӂ���\u001c���Q?l�E3\u001a?\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- 5�NSNF\b���tԫ�'\u0005\u0013|�\u0014�őt�`\u001ar��7�lο�G1�Ń��\b&˛nW��UY]�Ӳ�Uu��\u000f�y�l���ñ\u001f��R��|�[\u0013IH��� �\u001c�\n1���IU\"Z\u0011�g�_$�ݮ�q}�T�$�=��\u001b �����x\u0013P\"@FZǹ!���\".4JD.\u0001�M\u001a2��x�lN\u0001PR\u0004_�d�\u0016�Nƹ\u0002�1wH�%[R.J��ɘ�$ӚZM�L��\n�\u001f��%Y�?I&�H�r�$ɨfXcR�-\u0004��C��.Ǿ�񗣃�;��h�ޟM����{\u0006e��j������o��,��j��\u0019��r!U��耩��Wt޺�\u0005�V\u0002#�\u001d\u00069 ��.}���\b-�+�\u001c�tX�\"$g\u0011��&afCו i��\u0017�p\u0019���f�d\u0013�R�+��U�Q!��Y�X!�\u0018K[�$|\b>^\u0001HÜ���r���S�\u0016N�_\u0006���yvvxxr�\u0018yk�5���D\u0017�Ζo$Ҿ����\u0010�PAmZ��X�\f�D\u0011�\n+\fHC\u0001Z�H�\u0003���ؚ�Il���.�\u0010\u0016��<碴�����Z\u001f,}���\u0013�(dS�Mҡ��6��H2�S�\u0011Zx�գ�\u0006}��&_�\u0013�p����`��p�\f��!��\u0006�\\\u001am;�\u0002��\u0016`�NN\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- H�\\��j�@\u0010��}��l/��q�\u0001 ���\\�@�>��M*4�l�E޾���\u0016*�|��3�蘮����'����ݹ�\u001cz�\u0005w\u001e.�ufO��t};�\\���ԌI\u001a7��ɝ��0$umҷ�x���ܬ�a�n��%t.��hn>ֻ[��.���N�O&3˥��!&zj����L:o��vq���wq�_��ut���sʴC��cӺ���K�,\u001eKS?�c�8��[\u0017����lBR\u0017\bβ�\u0017���\u0010���\u0012�˜��\u000br\u0001.�%X�\u0002��\u0015X�\n�d\u000b�'߃\u0017�\u0005xE^E\u0016�\u0015�\u0015�\u0015�\u0015�\u0015�\u0015�\u0017�\u0017�\u0017�\u0017�\u0014�5y\nf��\u001e�\u001c\u001fT]1��\u0015{�Ћ�A᠌Q�(\u001d\u0014\u000e�x��ٻ�w���M�pS���]��Tz*\n>stream\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- H��V�N�H\u0010}�W�c���}����H \u00016+\u00023���*��L0lV\nf�\u0011��OU�\u0012�� 싻;�˩S]ǙdA<ޖ�媄\u000f\u001f�qY.W��װ���\u001e�œI�\u0013\u0016�0�\u0013\u0007��L\u0018c@k�h��� s2Eë����}\u000e���:�B��ӧ���nY��;��q2=� �2\u000e\u0002��@\b�5D\u001c�췊3��:�\u0012�6�\b���xNN\u0003 'EY\u0016�=��0Ӆi8S/Q�\u0014E�;�\u001c��2�\u0014d�] �o#\f�%\u0016�g�by\u0007S��ϏfSd�~�#��`�d\u001a�bZ9\u0010X0.�<�\u001b�I\u0016\b z��A�\u0019�\u0012�\u0015ԛ'\u0010�&_B\u0015\by�D�btq\u0012F\nF�sv\u0014\n|���,���E4|~_�N2%\u001cӺ���7{W��D�6\u000fP,��M�\b\u0015��4��q,,���m��\u0019n��\b>Y�>n�Z٭��Ԁ�I4\u001a��\\�Ad�`��&� >��p�\u0010�\u0016Ϊ�è\n��!��\u001c�Ƥ��j\u0013ij\n�i�i<�τ>���P\u001d�\u0010\u0003\na��>M\u001d�z\u001a�\u000b�;�d\u0015J�qd+3F1��3�\u0018�#\u0005�I��t�2i,�?\u0006,҃\u0016�����1À\u00043v!\u000e&\u0016�:l�\u000f���\u001b@�$h��z�\u0004(�\\�d��\u0004�\u001cN�`\"�F�|\u001c�&�2\\\f�U�\\��qs\u0006~�(�H�i��\u0013t/I\u0015�\u000b��Qg~8�a��'��\u0017�<\u000f#�u\u0011F\u0018�4�\u001c&�\u000e�0��\b\u001d�*��v���F-�pi*��x\u0010�!��|\n�y\u001cb\f\f~�u�*8C@�\"����6��Q���\u0019w�����,F�)\u0002%��\u0018���Jx\u0015F��\u000bZ�|�\u000f%ä��EI�\u0017����(b�{f��\u0018�4-������sN:�P���\\�v�\"��,�;T��;݊pԪ0��kX�[eI?$}���fD��Q\u001ez��5[��>^f��m7]�H,��ڦ��F�?B�i����\u0006����,��T \u0001�,\u0011~�S���� bs��\u000e`\u0005����\u0007\\���n�=b[�jK��&gL��\u001cx1�\u0015.�V��bCL�}i�5�\u0019�]\"\n�.\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- H�\\��n�@\u0010E���^&�ȯ� YH\u0004\u0012��<4�|��\u001bb)ؖ1\u000b�~��F\u0019i��c��{�JM����}7���44�0�S׷S�\u000e�� �\u0018�]��k�f��Z>�K=&i\\|�_�p���!�*���\u000f��tw\u000f�v8��$�1�a���{��=<��p\u001bǏp ��2�^�6��o����\u0004�.˞�m|�������/~�����:�L3��:�M���\u001c�*������k�����\u001a�\u001dO�{=%U�\u001fgY���L~\u0006��+�\u0005��;�+�\u0015�F��Uə%f�99\u0007\u0017�\u0002\\�K��\u0005��\u001e�d\u0005\u001b���,�Yҳ�g�!o\"\u000bs\u0005��\\A�0W�+�\u0015�\ns\u0005��\\A�0W�+�\u0015�\ns\u0005��\\Yrٕ�+aW���] �\u0012v%�ʳ+��<�=�=�=�=�=�=�=�=�=�===<�s\u0014s�s\u0014s�s\u0014s�s\u0014s�s\u0014s�{W�]9S��ܻb�ʽ+��ܻb��B~\u0001�\u0007E\u000f�\u001e\u0014=({P���Aу�\u0007C\u000fF�����o�7�\u001b�\n�F�����o�7�\u001b�\n�F��\nYE���� /��\\.����8�S��js��xL����|�dv}���\u0018���Ux'\u0005\u0018g/\n4\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- H�\\�Qk�@\u0014���\u0015��>\u0014\u0013u�MA\u0002ۤ�<�]6�\u001f`t�\u00156�L�C�}��.����3���5�춻�O.���v\u001f&w�c��e��6�C8�1[\u0016�����j�o�͘�y�LἋ�!�k�����)��ݏn8��,O]H}<��ߛ�����q�\u001b�!Nn��kׅ�\u0005�6�[s\u000e.��=�:��O�\u0007��o��m\f�����i�.\\Ʀ\n�����\u000b;֮~�c����w�Zq����iRV\u0017X�X��xE^�\u001fɏ�%הXS\u0016�\u0002,d1��3�ɘk*��Jr ��\u0015ؓ=�9՜�d\u0005ӡ�C�!o�[�\u0016�L~\u0006���x���������������������������� �(�(�\u0014d\n3\u0005��LA�0S�)�\u0014d\n;\n:\n߹��\u000b�%��O`v\u0017t\u0017v\u0017t\u0017v\u0017t\u0017v\u0017tWvWtWz*<��\nO���S��Tz*<��\nO���S�i'\f��$a��p�s�^S�\u0011�?�yv1�}\f�_�8��v�}\n0u�݇\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- ��JR%���B���j5��\u001c+��)\u0014�g(�ً%\u0006�!P�\u0013�\u000b\u0003�TPi˼����JWe�`�X�1�FK���W\u001f\u001e�ć�3�=\u0016k�6\u0006�n����9\u0016\u0002M\u0003�3\u0017f����\u001f�tJ�^�*�\u001c�_2�\u0007|r��\n=�z\u001b��(m\u000f�f��Hb�,K�O���>�eA�c>�\u0010���i\u0017\u0001�Fꡦ�\u0012h�E\n����y�{�\b�vC}ּ�ԉ\u0015��D�j했�D����R���V�����=\\\u000eզ\"D�\u0005��j0p�ą�x����_��\u001d\u0017+UI�U�\u0010��z�W�\u0016l�� 8A�]���_a}��k\u0015����T^��H\u0004\u0006��\u0015:H(\u001c��\bbr�a��B��{\"�pL�9r�]���\bf����9�\u001dG�_/<���nf8��fؐ�8a5r�\u0006촞����N���\u0005�~�T\u001f�w�!�d�4�$i I�4�H�B�Q�dlI?�D[m\u001b\u0006^ϑbn �?Ǥr\u0004�bZ1S� S�)Z�ZZ了L(�%�s\u000e�~�D\n����\u0012\u0013)�R�N)B6J��CY6\u0016\u001e5�a�M���z��>���I��\u001dha\u0011� <�s\u0003ء�e�!,)cs�Q��l�\u001aW*��Zz��^\u001b�uư�\f\u001d\u001c��~\u001b��v��w��P�:t��é�U�:�+o�\u0013��ڦ�\u0019K���XywG<��G��;�ĥ��\u0017{WM�\u001a�W��\n��o\nrK��p4��>��;�o\\�hl-M�.��쵵�M���`�ɋ���=�����\u0016d\u0001Eq}g.�\u001e?�_��\u0005���\u000e����snH\u001d\"\"�\u0014\f$<\u0012�\u0016�\u0010(\u0002F �\u0010\b�\u0010\b�$\u0004�<+�#C\u000b\n�C\u001eq� �@c\u0012����e}��Tq(-b�c\u000b�:�\"-\u00130Tk�\n����=�^B\u0012��xg~����={\u001e�?�}'7j�\nDG@���c�r��\u0017N�ݺ]ܪ6\"��V|�yw�\u001e֩�ʺ[�*[՚l�_�'U�;\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- H�d�w\\TW\u0016��;#Q\f (V|30���`�X\"b7&\u000b\u0016� �\u0006J�Œ�.v�-�\u001b��$����6�=q�Y���d��d�(�\f\u0002\"\u0016T,Q��3\u001a\u0013��}����������4�B\b�\u001a�\u0010\u00161̶-@�\\�995+%�#oQ9@�@#���kXV7=\nx���'3��d�^���Z�ʟ�9/#���r�u>��ojzJ����π�3z@����q�W\u0003�?�~�ԬܹqK>�\u0004ti�ǷΜ��Rz�\"\u0010��\u0001\u001azg����X��?b�\u001eo�L�J?Q��H�3�~�eϚ���\u0014\u0011��6������%N_��\u0002�\u000bJ��0��\u0014�.�\u0011[��|\u0011\u0019\\��FP�J�/���\u0017ix�a���5ȯ;\u0001x�q�\u0001���'�6�s��=��u\u0011�j�X�\u001e�i\u000f\n$\fQ��\u0016�\"ZJ+i\u0003m�ʹ�\n�\u001d��TA7�ɭ8�{p\"��$\u001eǩ�ϫx\u0003�㫢�S�H+ �v�]�e�,���Z��V�!�r^�T�*Z�)����fZkn����5����ǿ( 5`I�'\u0001O\f/��\u0011`X�`��\u0011nD\u001a�Fo���m�3\u0016\u0018+��\u0016����o1,VK���%Ғh�h�l�ne���embmjmimkmo\n�v�\u000e��X�\u00039�;�\u00124�\u0006\u001b�\n!�!\u0019!\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n\n## Key Issues, Risks, and Recommendations\n\n- Phone:\n1300 025 663\n(13 000 BLOOD)\nEmail:\nIgGovernance@blood.gov.au\nLast updated:\n07 May 2026\nBack to top\n Source: `pages/homepage.html (https://www.blood.gov.au/supply-system/governance-immunoglobulin-products/national-immunoglobulin-governance-committees)`\n- All\n2026\n2025\n2024\n2023\n2022\n2021\n2020\n2019\nNew BloodSafe eLearning Courses released\n07 Apr 2026\nCessation of supply of plasma-derived Factor IX\n07 Apr 2026\nNational Immunoglobulin Governance Program Update – November 2025\n19 Jan 2026\nNew James Isbister award sponsored by the National Blood Authority\n23 Oct 2025\n Source: `pages/news-latest.html (https://www.blood.gov.au/latest-updates)`\n- 640 0 obj\n<\n>/Filter/FlateDecode/ID[\n]/Index[628 21]/Info 627 0 R/Length 76/Prev 333197/Root 629 0 R/Size 649/Type/XRef/W[1 3 1]>>stream\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- endstream\nendobj\n629 0 obj\n<\n>/Metadata 41 0 R/Outlines 59 0 R/PageLayout/OneColumn/Pages 624 0 R/StructTreeRoot 104 0 R/Type/Catalog>>\nendobj\n630 0 obj\n<\n>/Font<\n>/XObject<\n>>>/Rotate 0/StructParents 0/Tabs/S/Type/Page>>\nendobj\n631 0 obj\n<\n>stream\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- hޤ�mO�0\u0010ǿ�_nB̏g;\u0012Bj\u0019eL�a\u0014�\u0006�E(\u0019�֦� \u0012|��m��t�\u0001S�^|�;�s?_��L0k\u0014�,�fZe��y\u0019�Ĥ��5�I�Šc� �66xow�~擺��=�?�O� ��1�A���v��p�I>�f~[��^^��iU�����o�5;�&o\n>ʣ��&�mn�����\u001a$�,��o>\u0015���aV+��HK�Z*>���5��Y������u\u0012:�1���\u0001.�� ����w[������\u0014\nQ->�Q���ӂ���\u001c���Q?l�E3\u001a?\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- 5�NSNF\b���tԫ�'\u0005\u0013|�\u0014�őt�`\u001ar��7�lο�G1�Ń��\b&˛nW��UY]�Ӳ�Uu��\u000f�y�l���ñ\u001f��R��|�[\u0013IH��� �\u001c�\n1���IU\"Z\u0011�g�_$�ݮ�q}�T�$�=��\u001b �����x\u0013P\"@FZǹ!���\".4JD.\u0001�M\u001a2��x�lN\u0001PR\u0004_�d�\u0016�Nƹ\u0002�1wH�%[R.J��ɘ�$ӚZM�L��\n�\u001f��%Y�?I&�H�r�$ɨfXcR�-\u0004��C��.Ǿ�񗣃�;��h�ޟM����{\u0006e��j������o��,��j��\u0019��r!U��耩��Wt޺�\u0005�V\u0002#�\u001d\u00069 ��.}���\b-�+�\u001c�tX�\"$g\u0011��&afCו i��\u0017�p\u0019���f�d\u0013�R�+��U�Q!��Y�X!�\u0018K[�$|\b>^\u0001HÜ���r���S�\u0016N�_\u0006���yvvxxr�\u0018yk�5���D\u0017�Ζo$Ҿ����\u0010�PAmZ��X�\f�D\u0011�\n+\fHC\u0001Z�H�\u0003���ؚ�Il���.�\u0010\u0016��<碴�����Z\u001f,}���\u0013�(dS�Mҡ��6��H2�S�\u0011Zx�գ�\u0006}��&_�\u0013�p����`��p�\f��!��\u0006�\\\u001am;�\u0002��\u0016`�NN\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- H�\\��j�@\u0010��}��l/��q�\u0001 ���\\�@�>��M*4�l�E޾���\u0016*�|��3�蘮����'����ݹ�\u001cz�\u0005w\u001e.�ufO��t};�\\���ԌI\u001a7��ɝ��0$umҷ�x���ܬ�a�n��%t.��hn>ֻ[��.���N�O&3˥��!&zj����L:o��vq���wq�_��ut���sʴC��cӺ���K�,\u001eKS?�c�8��[\u0017����lBR\u0017\bβ�\u0017���\u0010���\u0012�˜��\u000br\u0001.�%X�\u0002��\u0015X�\n�d\u000b�'߃\u0017�\u0005xE^E\u0016�\u0015�\u0015�\u0015�\u0015�\u0015�\u0015�\u0017�\u0017�\u0017�\u0017�\u0014�5y\nf��\u001e�\u001c\u001fT]1��\u0015{�Ћ�A᠌Q�(\u001d\u0014\u000e�x��ٻ�w���M�pS���]��Tz*\n>stream\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- H��V�N�H\u0010}�W�c���}����H \u00016+\u00023���*��L0lV\nf�\u0011��OU�\u0012�� 싻;�˩S]ǙdA<ޖ�媄\u000f\u001f�qY.W��װ���\u001e�œI�\u0013\u0016�0�\u0013\u0007��L\u0018c@k�h��� s2Eë����}\u000e���:�B��ӧ���nY��;��q2=� �2\u000e\u0002��@\b�5D\u001c�췊3��:�\u0012�6�\b���xNN\u0003 'EY\u0016�=��0Ӆi8S/Q�\u0014E�;�\u001c��2�\u0014d�] �o#\f�%\u0016�g�by\u0007S��ϏfSd�~�#��`�d\u001a�bZ9\u0010X0.�<�\u001b�I\u0016\b z��A�\u0019�\u0012�\u0015ԛ'\u0010�&_B\u0015\by�D�btq\u0012F\nF�sv\u0014\n|���,���E4|~_�N2%\u001cӺ���7{W��D�6\u000fP,��M�\b\u0015��4��q,,���m��\u0019n��\b>Y�>n�Z٭��Ԁ�I4\u001a��\\�Ad�`��&� >��p�\u0010�\u0016Ϊ�è\n��!��\u001c�Ƥ��j\u0013ij\n�i�i<�τ>���P\u001d�\u0010\u0003\na��>M\u001d�z\u001a�\u000b�;�d\u0015J�qd+3F1��3�\u0018�#\u0005�I��t�2i,�?\u0006,҃\u0016�����1À\u00043v!\u000e&\u0016�:l�\u000f���\u001b@�$h��z�\u0004(�\\�d��\u0004�\u001cN�`\"�F�|\u001c�&�2\\\f�U�\\��qs\u0006~�(�H�i��\u0013t/I\u0015�\u000b��Qg~8�a��'��\u0017�<\u000f#�u\u0011F\u0018�4�\u001c&�\u000e�0��\b\u001d�*��v���F-�pi*��x\u0010�!��|\n�y\u001cb\f\f~�u�*8C@�\"����6��Q���\u0019w�����,F�)\u0002%��\u0018���Jx\u0015F��\u000bZ�|�\u000f%ä��EI�\u0017����(b�{f��\u0018�4-������sN:�P���\\�v�\"��,�;T��;݊pԪ0��kX�[eI?$}���fD��Q\u001ez��5[��>^f��m7]�H,��ڦ��F�?B�i����\u0006����,��T \u0001�,\u0011~�S���� bs��\u000e`\u0005����\u0007\\���n�=b[�jK��&gL��\u001cx1�\u0015.�V��bCL�}i�5�\u0019�]\"\n�.\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- H�\\��n�@\u0010E���^&�ȯ� YH\u0004\u0012��<4�|��\u001bb)ؖ1\u000b�~��F\u0019i��c��{�JM����}7���44�0�S׷S�\u000e�� �\u0018�]��k�f��Z>�K=&i\\|�_�p���!�*���\u000f��tw\u000f�v8��$�1�a���{��=<��p\u001bǏp ��2�^�6��o����\u0004�.˞�m|�������/~�����:�L3��:�M���\u001c�*������k�����\u001a�\u001dO�{=%U�\u001fgY���L~\u0006��+�\u0005��;�+�\u0015�F��Uə%f�99\u0007\u0017�\u0002\\�K��\u0005��\u001e�d\u0005\u001b���,�Yҳ�g�!o\"\u000bs\u0005��\\A�0W�+�\u0015�\ns\u0005��\\A�0W�+�\u0015�\ns\u0005��\\Yrٕ�+aW���] �\u0012v%�ʳ+��<�=�=�=�=�=�=�=�=�=�===<�s\u0014s�s\u0014s�s\u0014s�s\u0014s�s\u0014s�{W�]9S��ܻb�ʽ+��ܻb��B~\u0001�\u0007E\u000f�\u001e\u0014=({P���Aу�\u0007C\u000fF�����o�7�\u001b�\n�F�����o�7�\u001b�\n�F��\nYE���� /��\\.����8�S��js��xL����|�dv}���\u0018���Ux'\u0005\u0018g/\n4\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- H�\\�Qk�@\u0014���\u0015��>\u0014\u0013u�MA\u0002ۤ�<�]6�\u001f`t�\u00156�L�C�}��.����3���5�춻�O.���v\u001f&w�c��e��6�C8�1[\u0016�����j�o�͘�y�LἋ�!�k�����)��ݏn8��,O]H}<��ߛ�����q�\u001b�!Nn��kׅ�\u0005�6�[s\u000e.��=�:��O�\u0007��o��m\f�����i�.\\Ʀ\n�����\u000b;֮~�c����w�Zq����iRV\u0017X�X��xE^�\u001fɏ�%הXS\u0016�\u0002,d1��3�ɘk*��Jr ��\u0015ؓ=�9՜�d\u0005ӡ�C�!o�[�\u0016�L~\u0006���x���������������������������� �(�(�\u0014d\n3\u0005��LA�0S�)�\u0014d\n;\n:\n߹��\u000b�%��O`v\u0017t\u0017v\u0017t\u0017v\u0017t\u0017v\u0017tWvWtWz*<��\nO���S��Tz*<��\nO���S�i'\f��$a��p�s�^S�\u0011�?�yv1�}\f�_�8��v�}\n0u�݇\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- ��JR%���B���j5��\u001c+��)\u0014�g(�ً%\u0006�!P�\u0013�\u000b\u0003�TPi˼����JWe�`�X�1�FK���W\u001f\u001e�ć�3�=\u0016k�6\u0006�n����9\u0016\u0002M\u0003�3\u0017f����\u001f�tJ�^�*�\u001c�_2�\u0007|r��\n=�z\u001b��(m\u000f�f��Hb�,K�O���>�eA�c>�\u0010���i\u0017\u0001�Fꡦ�\u0012h�E\n����y�{�\b�vC}ּ�ԉ\u0015��D�j했�D����R���V�����=\\\u000eզ\"D�\u0005��j0p�ą�x����_��\u001d\u0017+UI�U�\u0010��z�W�\u0016l�� 8A�]���_a}��k\u0015����T^��H\u0004\u0006��\u0015:H(\u001c��\bbr�a��B��{\"�pL�9r�]���\bf����9�\u001dG�_/<���nf8��fؐ�8a5r�\u0006촞����N���\u0005�~�T\u001f�w�!�d�4�$i I�4�H�B�Q�dlI?�D[m\u001b\u0006^ϑbn �?Ǥr\u0004�bZ1S� S�)Z�ZZ了L(�%�s\u000e�~�D\n����\u0012\u0013)�R�N)B6J��CY6\u0016\u001e5�a�M���z��>���I��\u001dha\u0011� <�s\u0003ء�e�!,)cs�Q��l�\u001aW*��Zz��^\u001b�uư�\f\u001d\u001c��~\u001b��v��w��P�:t��é�U�:�+o�\u0013��ڦ�\u0019K���XywG<��G��;�ĥ��\u0017{WM�\u001a�W��\n��o\nrK��p4��>��;�o\\�hl-M�.��쵵�M���`�ɋ���=�����\u0016d\u0001Eq}g.�\u001e?�_��\u0005���\u000e����snH\u001d\"\"�\u0014\f$<\u0012�\u0016�\u0010(\u0002F �\u0010\b�\u0010\b�$\u0004�<+�#C\u000b\n�C\u001eq� �@c\u0012����e}��Tq(-b�c\u000b�:�\"-\u00130Tk�\n����=�^B\u0012��xg~����={\u001e�?�}'7j�\nDG@���c�r��\u0017N�ݺ]ܪ6\"��V|�yw�\u001e֩�ʺ[�*[՚l�_�'U�;\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- H�d�w\\TW\u0016��;#Q\f (V|30���`�X\"b7&\u000b\u0016� �\u0006J�Œ�.v�-�\u001b��$����6�=q�Y���d��d�(�\f\u0002\"\u0016T,Q��3\u001a\u0013��}����������4�B\b�\u001a�\u0010\u00161̶-@�\\�995+%�#oQ9@�@#���kXV7=\nx���'3��d�^���Z�ʟ�9/#���r�u>��ojzJ����π�3z@����q�W\u0003�?�~�ԬܹqK>�\u0004ti�ǷΜ��Rz�\"\u0010��\u0001\u001azg����X��?b�\u001eo�L�J?Q��H�3�~�eϚ���\u0014\u0011��6������%N_��\u0002�\u000bJ��0��\u0014�.�\u0011[��|\u0011\u0019\\��FP�J�/���\u0017ix�a���5ȯ;\u0001x�q�\u0001���'�6�s��=��u\u0011�j�X�\u001e�i\u000f\n$\fQ��\u0016�\"ZJ+i\u0003m�ʹ�\n�\u001d��TA7�ɭ8�{p\"��$\u001eǩ�ϫx\u0003�㫢�S�H+ �v�]�e�,���Z��V�!�r^�T�*Z�)����fZkn����5����ǿ( 5`I�'\u0001O\f/��\u0011`X�`��\u0011nD\u001a�Fo���m�3\u0016\u0018+��\u0016����o1,VK���%Ғh�h�l�ne���embmjmimkmo\n�v�\u000e��X�\u00039�;�\u00124�\u0006\u001b�\n!�!\u0019!\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- �|̟��\u0003h\u0003�ѵ${��Z�ʣ�]I\u0006���^.2YO�\u0003*u\u0014�W#a�c��\u0001\u001b�:��V���I��xkՅ�\u0018�\\\u0001�\u0006�ԍ8��K��\nи��^S�̥MM4�LS�\u001aI%�\\�\u001b@F��)MSm)>H�h�\u0018�JRK+��7�1���4[�B�:���4ao\u001d1I.�oF�u\u000bv��7�\u0011�]��.\n<<2I���)'�%����7��^�\u0016�sie�\u0012M\u0015��W\u001a�xyY�7�\u0001\u001a��:��#$�y��I�\u0014aJNI$�7�oG����\u001c�<%Ԑi�J\u0015��%��02�QMer6\u0018�:L�\u0011�����ejK8$�>���XZ����\u001b�i�HӋod��P�\u000b�)E�>L�T��Ot�:Q��[%�\u0001�\u0004i]B��6ғ�&�ь�$��>�x\u0003\u0019KI�\u0003E��.�\u000f(�h�F\u0016��\u0014��F�\u0004j�P�kS�^�I#΄*4����`H#Q���z^p��I��\b�oJ�^_�\u0003x\n\u0017\u0017P����#le��Z�.#�I5���F��*��M9.h�hT!\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- 9$���x\u0003Ezз���\u0012��暔�R-5���\u0010�\u001a�Mn�#q�4�4��#h\u00027�PU\u0015,�Mg\u0004�G���X�����\u001b�c)i5[�B�:���4ao\u001d1I.�\u0006�\u0011�]BݭO\u0019zQ$�:\u0010�ӒO\u000f+���F�\u0017\n�y���&�t#I�+\u0019y~,��qu\u000bH��7�+Q��t�&��\u001bc-F@#F�\u0015f馜�4I4*\u0010���Y|�\u001b�h�Z\u0016�r��\\��*F�S[��T�\u001a�i���\u001cƚ��[$\u0006�\u0011�����ejk8$�<�5jǥ�g�\n�\nu*(,�F�\u0019GP\u001am�!u\u0005*o)�$\u001ai҅\b��a.���R�)�\u0012�N\\�y$�:1�%&�k��\u0003x\u000f�е ?�ѵ${��Z�ʣ�]I\u0006���^.2YO�\u0003*u\u0014�W#a�c��\u0001\u001b�:��V���I��xkՅ�\u0018�\\\u0001�\u0006�ԍ8��K��\nи��^S�̥MM4�LS�\u001aI%�\\�\u001b@F��)MSm)>H�h�\u0018�JRK+��7�1���4[�B�:���4ao\u001d1I.�oF�u\u000bv��7�\u0011�]��.\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n\n## Corporate Values and Operating Culture\n\n- The following, adapted from the Australian Public Service (APS) Code of Conduct, as set out in s 13\nof the PS Act, outline the conduct expectations of members:\n• Behave honestly and with integrity in the course of official activities\n• Treat everyone with respect and courtesy, and without harassment\n• Act with care and diligence\n• Comply with all applicable Australian laws\n• Maintain appropriate confidentiality\n• Disclose, and take reasonable steps to avoid, any conflict of interest (real or apparent)\n• Use Commonwealth resources in a proper manner\n• Do not disclose or make improper use of inside information\n• At all times behave in a way that upholds the integrity and good reputation of the NBA and\nthe Commonwealth.\n Source: `other-pdfs/National-20Immunoglobulin-20Governance-20Advisory-20Committee-20-28NIGAC-29-20--.pdf (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- [pages 1,2,3]\n[Page 1]\nSpecialist Working Group\nTerms of Reference\nOverview\nThe Specialist Working Groups (SWGs) were established to provide support to the National\nImmunoglobulin Governance Advisory Committee (NIGAC) and the National Blood Authority (NBA) with\nrespect to clinical considerations for the Immunoglobulin (Ig) Governance Program in each of the\nspeciality areas of Haematology, Immunology, Neurology and Transplantation.\n Source: `other-pdfs/SWG-20terms-20of-20reference.pdf (https://www.blood.gov.au/sites/default/files/documents/2024-08/SWG%20terms%20of%20reference.pdf)`\n- Phone:\n1300 025 663\n(13 000 BLOOD)\nEmail:\nIgGovernance@blood.gov.au\nLast updated:\n07 May 2026\nBack to top\n Source: `pages/homepage.html (https://www.blood.gov.au/supply-system/governance-immunoglobulin-products/national-immunoglobulin-governance-committees)`\n- All\n2026\n2025\n2024\n2023\n2022\n2021\n2020\n2019\nNew BloodSafe eLearning Courses released\n07 Apr 2026\nCessation of supply of plasma-derived Factor IX\n07 Apr 2026\nNational Immunoglobulin Governance Program Update – November 2025\n19 Jan 2026\nNew James Isbister award sponsored by the National Blood Authority\n23 Oct 2025\n Source: `pages/news-latest.html (https://www.blood.gov.au/latest-updates)`\n- 640 0 obj\n<\n>/Filter/FlateDecode/ID[\n]/Index[628 21]/Info 627 0 R/Length 76/Prev 333197/Root 629 0 R/Size 649/Type/XRef/W[1 3 1]>>stream\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- endstream\nendobj\n629 0 obj\n<\n>/Metadata 41 0 R/Outlines 59 0 R/PageLayout/OneColumn/Pages 624 0 R/StructTreeRoot 104 0 R/Type/Catalog>>\nendobj\n630 0 obj\n<\n>/Font<\n>/XObject<\n>>>/Rotate 0/StructParents 0/Tabs/S/Type/Page>>\nendobj\n631 0 obj\n<\n>stream\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- hޤ�mO�0\u0010ǿ�_nB̏g;\u0012Bj\u0019eL�a\u0014�\u0006�E(\u0019�֦� \u0012|��m��t�\u0001S�^|�;�s?_��L0k\u0014�,�fZe��y\u0019�Ĥ��5�I�Šc� �66xow�~擺��=�?�O� ��1�A���v��p�I>�f~[��^^��iU�����o�5;�&o\n>ʣ��&�mn�����\u001a$�,��o>\u0015���aV+��HK�Z*>���5��Y������u\u0012:�1���\u0001.�� ����w[������\u0014\nQ->�Q���ӂ���\u001c���Q?l�E3\u001a?\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n- 5�NSNF\b���tԫ�'\u0005\u0013|�\u0014�őt�`\u001ar��7�lο�G1�Ń��\b&˛nW��UY]�Ӳ�Uu��\u000f�y�l���ñ\u001f��R��|�[\u0013IH��� �\u001c�\n1���IU\"Z\u0011�g�_$�ݮ�q}�T�$�=��\u001b �����x\u0013P\"@FZǹ!���\".4JD.\u0001�M\u001a2��x�lN\u0001PR\u0004_�d�\u0016�Nƹ\u0002�1wH�%[R.J��ɘ�$ӚZM�L��\n�\u001f��%Y�?I&�H�r�$ɨfXcR�-\u0004��C��.Ǿ�񗣃�;��h�ޟM����{\u0006e��j������o��,��j��\u0019��r!U��耩��Wt޺�\u0005�V\u0002#�\u001d\u00069 ��.}���\b-�+�\u001c�tX�\"$g\u0011��&afCו i��\u0017�p\u0019���f�d\u0013�R�+��U�Q!��Y�X!�\u0018K[�$|\b>^\u0001HÜ���r���S�\u0016N�_\u0006���yvvxxr�\u0018yk�5���D\u0017�Ζo$Ҿ����\u0010�PAmZ��X�\f�D\u0011�\n+\fHC\u0001Z�H�\u0003���ؚ�Il���.�\u0010\u0016��<碴�����Z\u001f,}���\u0013�(dS�Mҡ��6��H2�S�\u0011Zx�գ�\u0006}��&_�\u0013�p����`��p�\f��!��\u0006�\\\u001am;�\u0002��\u0016`�NN\n Source: `pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)`\n\n## Global Ideas and Case Study Inputs\n\n_No global-intelligence source text found yet. Run `CLAUDE/global-ideas-scraper.py ` to populate case-study sources._\n\n## Source Artifacts Used\n\n- `pages/about.html` - pages - https://www.blood.gov.au/about-nba\n- `pages/homepage.html` - pages - https://www.blood.gov.au/supply-system/governance-immunoglobulin-products/national-immunoglobulin-governance-committees\n- `pages/news-latest.html` - pages - https://www.blood.gov.au/latest-updates\n- `pages/taskforces-index.html` - pages - https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf\n- `other-pdfs/SWG-20terms-20of-20reference.pdf` - other-pdfs - https://www.blood.gov.au/sites/default/files/documents/2024-08/SWG%20terms%20of%20reference.pdf\n- `other-pdfs/National-20Immunoglobulin-20Governance-20Advisory-20Committee-20-28NIGAC-29-20--.pdf` - other-pdfs - https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf\n\n## Gaps To Fix\n\n- No corporate plan text source found.\n- No annual report text source found.\n- No global comparison/case-study sources found.", "legislation_md": "# National Immunoglobulin Governance Advisory Committee - Acts and Legislation Discovery\n\n**Generated at**: 2026-05-09T21:11:49.345359+00:00\n**Entity ID**: B-003292\n**Jurisdiction**: Commonwealth\n**Portfolio**: Health, Disability and Ageing\n\n> This is an evidence-based discovery list from scraped department material. A mention does not always mean the department administers the legislation; high-confidence and official register links should be reviewed.\n\n## Summary\n\n- Source files scanned: 7\n- Unique legislation references found: 4\n\n| Type | Count |\n|---|---:|\n| Act | 4 |\n\n## Legislation References\n\n### National Blood Authority Act 2003\n\n**Type**: Act\n**Confidence**: high\n**Mentions**: 3\n**Register search**: https://www.legislation.gov.au/search?query=National+Blood+Authority+Act+2003\n\n**Sources**:\n- `pages/about.html`\n- `pages/homepage.html`\n- `other-pdfs/National-20Immunoglobulin-20Governance-20Advisory-20Committee-20-28NIGAC-29-20--.pages.jsonl`\n\n**Evidence contexts**:\n- About NBA | National Blood Authority\n\nWho we are\nWe are a statutory agency established by the\nNational Blood Authority Act 2003\n(Cth)\n(Opens in a new tab/window)\n. We operate to achieve the policy objectives outlined in the\nNational Blood Agreement\n.\nWe manage and coordinate arrangements for the supply of blood, blood products and blood services in Australia. Under the national blood\n Source: `pages/about.html`\n- roups, see our\nlatest updates\n.\nNational Immunoglobulin Governance Advisory Committee\nOur peak Ig governance committee is the National Immunoglobulin Governance Advisory Committee (NIGAC). The NIGAC is a statutory committee established under section 38 of the\nNational Blood Authority Act 2003\n(Cth)\n(Opens in a new tab/window)\n.\nThe NIGAC meets up to 3 times a year. The committee provides advice and makes recommendations about our Ig governance program.\nThe committee helps to ensure access to government-funded Ig is fair and equitable. It also aims\n Source: `pages/homepage.html`\n- erence\nCommittee procedures\nFebruary 2026\nOFFICIAL\n\n[page 2]\nOFFICIAL\nRole\nPurpose\nThe National Immunoglobulin Governance Advisory Committee (NIGAC) is established by the\nNational Blood Authority (NBA) General Manager (Chief Executive) under section 38 of the\nNational Blood Authority Act 2003 (NBA Act) to assist with the performance of the NBA’s\nfunctions in relation to the National Immunoglobulin (Ig) Governance Program (the Program).\nAs the peak committee within the Ig governance national network of committees, NIGAC is\nestablished to fulfil the\n Source: `other-pdfs/National-20Immunoglobulin-20Governance-20Advisory-20Committee-20-28NIGAC-29-20--.pages.jsonl`\n\n### Freedom of Information Act 1982\n\n**Type**: Act\n**Confidence**: low\n**Mentions**: 1\n**Register search**: https://www.legislation.gov.au/search?query=Freedom+of+Information+Act+1982\n\n**Sources**:\n- `other-pdfs/National-20Immunoglobulin-20Governance-20Advisory-20Committee-20-28NIGAC-29-20--.pages.jsonl`\n\n**Evidence contexts**:\n- disclosed that are relevant to the meeting agenda are accurately\nreflected in the record of the meeting.\nMembers endorse the record of a meeting at their subsequent meeting. Members should be aware\nthat the record of meetings fall within the provisions of the Freedom of Information Act 1982.\nReporting\nEvery three years, to align with the end of the triennial appointment term, NIGAC shall provide a\nwritten triennial report to the NBA CE summarising its outcomes for the triennium. The report\nshould include:\n• A summary of the work NIGAC performed\n Source: `other-pdfs/National-20Immunoglobulin-20Governance-20Advisory-20Committee-20-28NIGAC-29-20--.pages.jsonl`\n\n### NBA Act and the Remuneration Tribunal Act 1973\n\n**Type**: Act\n**Confidence**: low\n**Mentions**: 1\n**Register search**: https://www.legislation.gov.au/search?query=NBA+Act+and+the+Remuneration+Tribunal+Act+1973\n\n**Sources**:\n- `other-pdfs/National-20Immunoglobulin-20Governance-20Advisory-20Committee-20-28NIGAC-29-20--.pages.jsonl`\n\n**Evidence contexts**:\n- sent or act on behalf of the NBA, unless specifically directed by the NBA CE or their\ndelegate to do so.\nRemuneration and allowances\nNIGAC members are to be paid the remuneration and allowances as determined by the\nRemuneration Tribunal in accordance with the NBA Act and the Remuneration Tribunal Act\n1973.\nOut of session activities\nNIGAC can help or advise the NBA outside of regular meetings. This process should follow the\nusual meeting procedures as much as possible.\nMembers may be called upon for ad-hoc advice via email between meetings. When committee\nbusin\n Source: `other-pdfs/National-20Immunoglobulin-20Governance-20Advisory-20Committee-20-28NIGAC-29-20--.pages.jsonl`\n\n### NBA Act, Public Service Act 1999\n\n**Type**: Act\n**Confidence**: low\n**Mentions**: 1\n**Register search**: https://www.legislation.gov.au/search?query=NBA+Act%2C+Public+Service+Act+1999\n\n**Sources**:\n- `other-pdfs/National-20Immunoglobulin-20Governance-20Advisory-20Committee-20-28NIGAC-29-20--.pages.jsonl`\n\n**Evidence contexts**:\n- meeting progresses.\nDetails of any conflicts will be recorded in the meeting minutes. The secretariat will maintain\nthe register of DoIs.\nConduct\nMembers of NIGAC are appointed as part-time office holders and are considered ‘officials’ for the\npurposes of the NBA Act, Public Service Act 1999 (PS Act), PGPA Act and other relevant legislation.\nMembers are expected to conduct themselves in a manner consistent with being an office holder\nof the Commonwealth.\nThe following, adapted from the Australian Public Service (APS) Code of Conduct, as set out i\n Source: `other-pdfs/National-20Immunoglobulin-20Governance-20Advisory-20Committee-20-28NIGAC-29-20--.pages.jsonl`\n\n## Files Scanned\n\n- `pages/about.html` (page)\n- `pages/contact.html` (page)\n- `pages/homepage.html` (page)\n- `pages/news-latest.html` (page)\n- `pages/taskforces-index.html` (page)\n- `other-pdfs/National-20Immunoglobulin-20Governance-20Advisory-20Committee-20-28NIGAC-29-20--.pages.jsonl` (pdf_pages)\n- `other-pdfs/SWG-20terms-20of-20reference.pages.jsonl` (pdf_pages)", "global_initiatives_md": null, "strategy": { "reporting_period": "2024-25", "corporate_plan_period": "2025-26", "vision": null, "vision_source_page": null, "purposes": "The National Immunoglobulin Governance Advisory Committee (NIGAC) is established by the National Blood Authority (NBA) General Manager (Chief Executive) under section 38 of the National Blood Authority Act 2003 (NBA Act) to assist with the performance of the NBA’s functions in relation to the National Immunoglobulin (Ig) Governance Program (the Program).", "purposes_source_page": 2, "how_we_deliver": "The Program is delivered through a package of measures which implements an integrated national framework for governance and management of immunoglobulin products.", "how_we_deliver_source_page": 7, "government_priorities": [ { "text": "Provide advice and make recommendations to the NBA to support the Program", "source_page": 7 }, { "text": "Provide advice and make recommendations to support cost effective and clinically appropriate governance, management and use of Ig products, including advice and recommendations in relation to each of the performance areas within the Program", "source_page": 7 }, { "text": "When requested by the NBA, provide advice or assistance to other parties on matters concerning the availability, governance, management or use of Ig products.", "source_page": 7 } ], "outcomes": [ { "name": "Outcome 1: Governance and management of immunoglobulin products", "description": "The Program aims to ensure product use and management reflects appropriate clinical practice, represents efficient, effective and ethical expenditure of government funds, is in accordance with relevant national safety and quality standards for health care, and ensures that access to Ig products is consistent with the criteria for access determined by Governments.", "key_activities": [ "Development and maintenance of policies and procedures for access to Ig products", "Establishment and support of a national network of committees", "Evolving the criteria for access", "Development and implementation of a national ordering and outcomes database", "Improving performance", "Facilitating knowledge development", "Potential efficiency improvements" ], "source_page": 8 } ], "values": [ "Behave honestly and with integrity", "Treat everyone with respect and courtesy", "Act with care and diligence", "Comply with all applicable Australian laws", "Maintain appropriate confidentiality", "Disclose, and take reasonable steps to avoid, any conflict of interest", "Use Commonwealth resources in a proper manner", "Do not disclose or make improper use of inside information" ], "values_framework_name": "Australian Public Service (APS) Code of Conduct", "kpi_targets_2025_26": [ { "code": "Ig01", "measure": "Automated authorisation of access to Ig products", "target": "Feasible and appropriate", "source_page": 9 }, { "code": "Ig02", "measure": "Improved efficiency through streamlined product distribution", "target": "N/A", "source_page": 9 } ], "kpi_results_2024_25": [ { "code": "Ig01", "measure": "Automated authorisation of access to Ig products", "result": "N/A", "status": "Not achieved", "source_page": null }, { "code": "Ig02", "measure": "Improved efficiency through streamlined product distribution", "result": "N/A", "status": "Not achieved", "source_page": null } ], "_source_urls": { "annual_report_url": "https://www.blood.gov.au/sites/default/files/documents/2025-10/NBA0920%20%E2%80%93%20NBA%20Annual%20Report%202024%E2%80%9325%20%28Working%20file%29%20-%20WCAG.pdf", "corporate_plan_url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf" } }, "ideas": [ { "entity_id": "B-003292", "entity_name": "National Immunoglobulin Governance Advisory Committee", "folder_name": "National-Immunoglobulin-Governance-Advisory-Committee", "category": "Data & Performance", "scale": "small", "title": "KPI evidence register with named owners", "idea": "Create a simple register mapping each KPI to source data, owner, frequency, target, and last result.", "quote": "endstream\nendobj\n629 0 obj\n<\n>/Metadata 41 0 R/Outlines 59 0 R/PageLayout/OneColumn/Pages 624 0 R/StructTreeRoot 104 0 R/Type/Catalog>>\nendobj\n630 0 obj\n<\n>/Font<\n>/XObject<\n>>>/Rotate 0/StructParents 0/Tabs/S/Type/Page>>\nendobj\n631 0 obj\n<\n>stream", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Executives / Parliament / public", "source": "pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability" ] }, { "entity_id": "B-003292", "entity_name": "National Immunoglobulin Governance Advisory Committee", "folder_name": "National-Immunoglobulin-Governance-Advisory-Committee", "category": "Data & Performance", "scale": "large", "title": "Outcome dashboard linking budget, delivery, and public impact", "idea": "Build a public-facing outcome dashboard showing spend, outputs, outcomes, and delivery confidence.", "quote": "endstream\nendobj\n629 0 obj\n<\n>/Metadata 41 0 R/Outlines 59 0 R/PageLayout/OneColumn/Pages 624 0 R/StructTreeRoot 104 0 R/Type/Catalog>>\nendobj\n630 0 obj\n<\n>/Font<\n>/XObject<\n>>>/Rotate 0/StructParents 0/Tabs/S/Type/Page>>\nendobj\n631 0 obj\n<\n>stream", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Executives / Parliament / public", "source": "pages/taskforces-index.html (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability" ] }, { "entity_id": "B-003292", "entity_name": "National Immunoglobulin Governance Advisory Committee", "folder_name": "National-Immunoglobulin-Governance-Advisory-Committee", "category": "Risk & Assurance", "scale": "small", "title": "Recommendation tracker for audits, reviews, and inquiries", "idea": "Publish a single internal tracker for audit/review recommendations, owners, due dates, and implementation evidence.", "quote": "The following, adapted from the Australian Public Service (APS) Code of Conduct, as set out in s 13\nof the PS Act, outline the conduct expectations of members:\n• Behave honestly and with integrity in the course of official activities\n• Treat everyone with respect and courtesy, and without harassment\n• Act with care and diligence\n• Comply with all applicable Australian laws\n• Maintain appropriate confidentiality\n• Disclose, and take reasonable steps to avoid, any conflict of interest (real or apparent)\n• Use Commonwealth resources in a proper manner\n• Do not disclose or make improper use of inside information\n• At all times behave in a way that upholds the integrity and good reputation of the NBA and\nthe Commonwealth.", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Executives / assurance teams", "source": "other-pdfs/National-20Immunoglobulin-20Governance-20Advisory-20Committee-20-28NIGAC-29-20--.pdf (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Regulatory capture", "Over-automation of judgement" ] }, { "entity_id": "B-003292", "entity_name": "National Immunoglobulin Governance Advisory Committee", "folder_name": "National-Immunoglobulin-Governance-Advisory-Committee", "category": "Risk & Assurance", "scale": "large", "title": "Integrated assurance and lessons-learned system", "idea": "Create an assurance system that connects audit findings, risk registers, delivery reviews, and investment decisions.", "quote": "The following, adapted from the Australian Public Service (APS) Code of Conduct, as set out in s 13\nof the PS Act, outline the conduct expectations of members:\n• Behave honestly and with integrity in the course of official activities\n• Treat everyone with respect and courtesy, and without harassment\n• Act with care and diligence\n• Comply with all applicable Australian laws\n• Maintain appropriate confidentiality\n• Disclose, and take reasonable steps to avoid, any conflict of interest (real or apparent)\n• Use Commonwealth resources in a proper manner\n• Do not disclose or make improper use of inside information\n• At all times behave in a way that upholds the integrity and good reputation of the NBA and\nthe Commonwealth.", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Executives / assurance teams", "source": "other-pdfs/National-20Immunoglobulin-20Governance-20Advisory-20Committee-20-28NIGAC-29-20--.pdf (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Regulatory capture", "Over-automation of judgement" ] }, { "entity_id": "B-003292", "entity_name": "National Immunoglobulin Governance Advisory Committee", "folder_name": "National-Immunoglobulin-Governance-Advisory-Committee", "category": "Citizen Services", "scale": "small", "title": "Plain-language service pages and proactive status updates", "idea": "Rewrite high-volume pages and letters into plain language, add status notifications, and measure contact reduction.", "quote": "[Page 8]\nOFFICIAL\nThe specific implementation arrangements may vary according to the circumstances of different\njurisdictions or health services, within the objective of ensuring nationally consistent Ig governance\nand management outcomes.", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Citizens / service users", "source": "other-pdfs/National-20Immunoglobulin-20Governance-20Advisory-20Committee-20-28NIGAC-29-20--.pdf (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Digital exclusion", "Low public trust if feedback is not acted on" ] }, { "entity_id": "B-003292", "entity_name": "National Immunoglobulin Governance Advisory Committee", "folder_name": "National-Immunoglobulin-Governance-Advisory-Committee", "category": "Citizen Services", "scale": "large", "title": "Single front door for life-event based services", "idea": "Bundle services around life events so citizens can complete related steps across agencies in one journey.", "quote": "[Page 8]\nOFFICIAL\nThe specific implementation arrangements may vary according to the circumstances of different\njurisdictions or health services, within the objective of ensuring nationally consistent Ig governance\nand management outcomes.", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Citizens / service users", "source": "other-pdfs/National-20Immunoglobulin-20Governance-20Advisory-20Committee-20-28NIGAC-29-20--.pdf (https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Digital exclusion", "Low public trust if feedback is not acted on" ] }, { "entity_id": "B-003292", "entity_name": "National Immunoglobulin Governance Advisory Committee", "folder_name": "National-Immunoglobulin-Governance-Advisory-Committee", "category": "Citizen Participation", "scale": "small", "title": "Consultation feedback summaries with response tracking", "idea": "Summarise consultation submissions by theme and publish what changed in response.", "quote": "Medical Specialty Representatives*: NBA to appoint members based on\nEach SWG must have a minimum of 5 members consultation with Jurisdictional government\nand include: health departments and other relevant\n– Representation from both adult and stakeholders.\npaediatric specialities (where relevant) Each relevant SWG will include at least 1\n– Members from at least 4 jurisdictions representative from the relevant society:\n*Persons with clinical expertise and appropriate – Neurology Group - Australian and New\nqualifications to consider the clinical Zealand Association of\nappropriateness, safety and cost effectiveness of Neurologists(ANZAN)\nIg, including comparative outcomes of different – Haematology Group - Haematology Society\ntherapies. of Australia and New Zealand (HSANZ)\n– Immunology Group - Australasian Society\nof Clinical Immunology and Allergy (ASCIA)", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "Citizens / stakeholders / policy teams", "source": "other-pdfs/SWG-20terms-20of-20reference.pdf (https://www.blood.gov.au/sites/default/files/documents/2024-08/SWG%20terms%20of%20reference.pdf)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Digital exclusion", "Low public trust if feedback is not acted on" ] }, { "entity_id": "B-003292", "entity_name": "National Immunoglobulin Governance Advisory Committee", "folder_name": "National-Immunoglobulin-Governance-Advisory-Committee", "category": "Citizen Participation", "scale": "large", "title": "Always-on policy participation platform", "idea": "Create a standing participation platform where citizens and stakeholders can propose, vote, and track ideas.", "quote": "Medical Specialty Representatives*: NBA to appoint members based on\nEach SWG must have a minimum of 5 members consultation with Jurisdictional government\nand include: health departments and other relevant\n– Representation from both adult and stakeholders.\npaediatric specialities (where relevant) Each relevant SWG will include at least 1\n– Members from at least 4 jurisdictions representative from the relevant society:\n*Persons with clinical expertise and appropriate – Neurology Group - Australian and New\nqualifications to consider the clinical Zealand Association of\nappropriateness, safety and cost effectiveness of Neurologists(ANZAN)\nIg, including comparative outcomes of different – Haematology Group - Haematology Society\ntherapies. of Australia and New Zealand (HSANZ)\n– Immunology Group - Australasian Society\nof Clinical Immunology and Allergy (ASCIA)", "impact": "Very High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "Citizens / stakeholders / policy teams", "source": "other-pdfs/SWG-20terms-20of-20reference.pdf (https://www.blood.gov.au/sites/default/files/documents/2024-08/SWG%20terms%20of%20reference.pdf)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Digital exclusion", "Low public trust if feedback is not acted on" ] }, { "entity_id": "B-003292", "entity_name": "National Immunoglobulin Governance Advisory Committee", "folder_name": "National-Immunoglobulin-Governance-Advisory-Committee", "category": "Staff Productivity", "scale": "small", "title": "Reusable briefing and summary assistant for internal documents", "idea": "Create controlled templates for summarising reports, submissions, minutes, and ministerial briefs.", "quote": "Clinical Associate Professor, Department of Medicine, University of Adelaide\nMedical specialist – neurology\nAssociate Professor Stephen Reddel, Staff Specialist Neurologist, Concord Repatriation General Hospital, New South Wales\nMedical specialist – transplant medicine\nAssociate Professor Ross Francis\n,\nSenior Staff Specialist - Kidney Medicine/Kidney Transplantation, Princess Alexandra Hospital, Brisbane, Queensland\nConsumer representatives (2)\nDr Lisa Wright, Myasenthia Alliance Australia (MAA) board member; committee member of Myasenthia Gravis Association of Queensland (MGAQ)\nMs Jackie Murphy,\nPresident, Australian Primary Immune Deficiency Patient Support (AusPIPS)\nDispenser representative\nMs Kylie Fitch, Assistant Manager, Sullivans Nicolaides Pathology, Corporate Blood Bank, Bowen Hills, Queensland\nEpidemiologist", "impact": "High", "effort": "Low", "proof": "Evidence-backed", "beneficiaries": "APS staff / executives", "source": "pages/homepage.html (https://www.blood.gov.au/supply-system/governance-immunoglobulin-products/national-immunoglobulin-governance-committees)", "implementation": [ "Pick one high-volume process or document family.", "Name an owner and baseline current volume, time, cost, and satisfaction.", "Run a 4-8 week pilot with clear before/after metrics.", "Publish lessons and decide whether to scale." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Sensitive information leakage", "Inconsistent quality of generated drafts" ] }, { "entity_id": "B-003292", "entity_name": "National Immunoglobulin Governance Advisory Committee", "folder_name": "National-Immunoglobulin-Governance-Advisory-Committee", "category": "Staff Productivity", "scale": "large", "title": "Department-wide knowledge and briefing platform", "idea": "Build a secure knowledge platform that lets staff search, summarise, and cite approved departmental material.", "quote": "Clinical Associate Professor, Department of Medicine, University of Adelaide\nMedical specialist – neurology\nAssociate Professor Stephen Reddel, Staff Specialist Neurologist, Concord Repatriation General Hospital, New South Wales\nMedical specialist – transplant medicine\nAssociate Professor Ross Francis\n,\nSenior Staff Specialist - Kidney Medicine/Kidney Transplantation, Princess Alexandra Hospital, Brisbane, Queensland\nConsumer representatives (2)\nDr Lisa Wright, Myasenthia Alliance Australia (MAA) board member; committee member of Myasenthia Gravis Association of Queensland (MGAQ)\nMs Jackie Murphy,\nPresident, Australian Primary Immune Deficiency Patient Support (AusPIPS)\nDispenser representative\nMs Kylie Fitch, Assistant Manager, Sullivans Nicolaides Pathology, Corporate Blood Bank, Bowen Hills, Queensland\nEpidemiologist", "impact": "High", "effort": "High", "proof": "Evidence-backed", "beneficiaries": "APS staff / executives", "source": "pages/homepage.html (https://www.blood.gov.au/supply-system/governance-immunoglobulin-products/national-immunoglobulin-governance-committees)", "implementation": [ "Create a senior responsible owner and cross-functional delivery team.", "Map legislation, data, privacy, procurement, cyber, and workforce constraints.", "Co-design with users and frontline staff before technology selection.", "Stage delivery through pilots, benefits tracking, and public reporting." ], "risks": [ "Privacy and data quality", "Change fatigue", "Unclear accountability", "Sensitive information leakage", "Inconsistent quality of generated drafts" ] } ], "legislation_administered": [], "artifacts": [ { "category": "other-pdfs", "year": "2026", "url": "https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf", "file": "other-pdfs/National-20Immunoglobulin-20Governance-20Advisory-20Committee-20-28NIGAC-29-20--.pdf", "bytes": 397687, "link_text": "National Immunoglobulin Governance Advisory Committee (NIGAC) - Terms of Reference - February 2026.pdf" }, { "category": "other-pdfs", "year": "2024", "url": "https://www.blood.gov.au/sites/default/files/documents/2024-08/SWG%20terms%20of%20reference.pdf", "file": "other-pdfs/SWG-20terms-20of-20reference.pdf", "bytes": 224329, "link_text": "SWG terms of reference.pdf" }, { "category": "annual-reports", "year": "2025", "url": "https://www.blood.gov.au/sites/default/files/documents/2025-10/NBA0920%20%E2%80%93%20NBA%20Annual%20Report%202024%E2%80%9325%20%28Working%20file%29%20-%20WCAG.pdf", "file": "annual-reports/2025.pdf", "bytes": 3522745, "link_text": "Annual Report" }, { "category": "corporate-plans", "year": "2025", "url": "https://www.blood.gov.au/sites/default/files/documents/2025-08/NBA%20Corporate%20Plan%202025-26%20-%20Final.pdf", "file": "corporate-plans/2025.pdf", "bytes": 6435684, "link_text": "Corporate Plan" } ], "_meta": { "snapshot_built_at": "2026-05-13T11:02:56+00:00", "strategy_brief_meta": { "model": "nova-micro", "folder": "National-Immunoglobulin-Governance-Advisory-Committee", "annual_report": { "file": null, "url": "", "year": null }, "corporate_plan": { "file": "other-pdfs\\National-20Immunoglobulin-20Governance-20Advisory-20Committee-20-28NIGAC-29-20--.txt", "url": "https://www.blood.gov.au/sites/default/files/documents/2026-02/National%20Immunoglobulin%20Governance%20Advisory%20Committee%20%28NIGAC%29%20-%20Terms%20of%20Reference%20-%20February%202026.pdf", "year": null }, "usage": { "input_tokens": 5618, "output_tokens": 861, "total_tokens": 6479, "model": "nova-micro" }, "cost_usd": 0.00031717000000000003, "elapsed_seconds": 2.88, "generated_at": "2026-05-13T10:33:36+00:00" }, "ideas_manifest": { "entity_id": "B-003292", "entity_name": "National Immunoglobulin Governance Advisory Committee", "folder_name": "National-Immunoglobulin-Governance-Advisory-Committee", "generated_at": "2026-05-09T23:05:41.551856+00:00", "idea_count": 10, "markdown": "ideas/National-Immunoglobulin-Governance-Advisory-Committee_ideas.md", "jsonl": "ideas/ideas.jsonl", "inputs": [ "National-Immunoglobulin-Governance-Advisory-Committee_strategy-overview.md", "strategy-evidence.json", "global-intelligence/source-manifest.json" ] }, "global_intel_meta": null } }